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I. INTRODUCTION
Legislation, regulation, scholarship, and journalism addressing the opioid
crisis have focused on a number of front-end management strategies,
including opioid production quotas,' opioid taxes, 2 drug labeling, 3 risk
evaluation and mitigation strategies, 4 marketing restrictions,' physician
prescribing practices, 6 prescription drug monitoring programs,7 prescription
1. See, e.g., Scott Burris et al., Stopping an Invisible Epidemic: Legal Issues in the
Provision of Naloxone to Prevent Opioid Overdose, 1 DREXEL L. REV. 273, 286 (2009)
(discussing production quotas as well as eradication programs, border controls, and street-level
disruptions as supply-side interventions that can help interfere with the production and
distribution of opioids and other drugs).
2. See, e.g., Editorial, Kill Cuomo's Cockamamie 'Opioid Tax', N.Y. POST (Mar. 22,
2018, 7:09 PM), https://nypost.com/2018/03/22/kill-cuomos-cockamamie-opioid-tax
(criticizing Governor Andrew Cuomo's proposed two-cents-per-milligram opioid tax, also
known as an "opioid epidemic surcharge," and questioning whether pharmaceutical companies
would actually pay the tax).
3. See, e.g., Patricia J. Zettler, Margaret Foster Riley & Aaron S. Kesselheim,
Implementing a Public Health Perspective in FDA Drug Regulation, 73 FOOD & DRUG L.J. 221,
221 (2018) (discussing the FDA's influence on provider and patient behavior through drug
labeling).
4. See, e.g., Hilary Homenko, Rehabilitating Opioid Regulation: A Prescription for the
FDA's Next Proposal of an Opioid Risk Evaluation and Mitigation Strategy (REMS), 22
HEALTH MATRIx 273, 290-313 (2012) (discussing the FDA's authority to require a risk
evaluation and mitigation strategy (REMS) as part of a drug approval application; applying
REMS to the opioid crisis).
5. See, e.g., Ameet Sarpatwari et al., The Opioid Epidemic: Fixing a Broken
Pharmaceutical Market, 11 HARV. L. & POL'Y REV. 463, 472-73 (2017) ("[I]neffective
penalties for illegal marketing incentivized [opioid manufacturers] to make misleading
claims.").
6. See, e.g., Kelly K. Dineen, Addressing Prescription Opioid Abuse Concerns in
Context: Synchronizing Policy Solutions to Multiple Complex Public Health Problems, 40 L. &
PSYCH. REV. 1 (2016) (examining prescription opioid policy in light of available morbidity and
mortality data and suggesting areas of policy priority that better align with evidence); Kelly K.
Dineen, Definitions Matter: Defining Inappropriate Prescribing to Shape Effective Opioid
Policy and Reduce Patient Harm, 67 KAN. L. REV. (forthcoming 2019) (assessing opioid
prescribing policy and the lack of definitions for inappropriate prescribing; offering a new
framework for inappropriate prescribing); Kelly K. Dineen & James M. Dubois, Between a Rock
and a Hard Place: Can Physicians Prescribe Opioids to Treat Pain Adequately While Avoiding
Legal Sanction? 42 AM. J. L. & MED. 1, 7-52 (2016) (reviewing cases of inappropriate
prescribing and suggesting a new framework for describing and categorizing inappropriate
prescribers).
7. See, e.g., Jennifer Oliva, Prescription Drug Policing: The Right to Protected Health
Information Privacy Pre- and Post-Carpenter, 69 DUKE L.J. (forthcoming 2020) (arguing that
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safety alert systems,6 maximum initial opioid prescription quantities, 9
continuing opioid education for opioid prescribers,' 0 and temporary
restraining orders for improper opioid prescribers." Back-end crisis-
management strategies, including needle exchange programs,' 2 safe injection
sites,13 opioid reversal agent availability, 14 medication-assisted treatment, 15
mobile health care services, 16 mobile application-mediated prescription
courts are more likely to rule that warrantless Drug Enforcement Agency (DEA) searches of
sensitive health care data stored in prescription drug monitoring program (PDMP) databases
violate the Fourth Amendment post-Carpenter v. United States).
8. See, e.g., Rx Safety Alert Systems, MCKESSON, https://www.mckesson.com/about-
mckesson/fighting-opioid-abuse/rx-safety-alert-system (last visited Mar. 18, 2019). McKesson
is developing a prescription safety alert system, which is a "nationwide clinical alert system that
uses patient prescription history to identify patients at risk for opioid overuse, abuse, addiction
or misuse. The system would provide proactive, real-time clinical alerts, integrated into
pharmacist workflow, across state lines." Id.
9. See, e.g., An Act Relating to Regulation of Opioid Drugs, OKLA. S.B. 1446, § 5 (eff.
Nov. 1, 2018) (prohibiting practitioners from issuing an initial prescription for an opioid drug in
a quantity exceeding a seven-day supply for treatment of acute pain in an adult patient or a
patient under the age of eighteen; further requiring any opioid prescription for acute pain to be
for the lowest effective dose of the immediate-release version of the opioid drug).
10. See, e.g., id. § 1(C) (requiring Oklahoma licensed physicians who have DEA numbers
to take at least one hour of continuing education in the area of pain management or opioid
addiction prior to license renewal).
11. See, e.g., Alex Ebert, DOJRestraining Orders Strip Does' Opioid Prescribing Rights
(1), BLOOMBERG L. NEWS (Aug. 22, 2018, 3:40 PM), https://news.bloomberglaw.com/health-
law-and-business/doj-restraining-orders-strip-docs-opioid-prescribing-rights-1 (reporting that
the U.S. Department of Justice (DOJ) is using civil temporary restraining orders to prevent
physicians from writing improper opioid prescriptions while under investigation for illegal
conduct; also reporting that the DOJ used the emergency orders against two Ohio physicians
who were allegedly caught giving opioids to undercover patients who did not need the opioids).
12. See, e.g., Melissa Vallejo, Note, Safer Bathrooms in Syringe Exchange Programs:
Injecting Progress into the Harm Reduction Movement, 118 COLUM. L. REv. 1185, 1211-24
(2018) (advocating for safe bathrooms as part of syringe exchange programs).
13. See, e.g., Alex H. Kral & Peter J. Davidson, Addressing the Nation's Opioid
Epidemic: Lessons from an Unsanctioned Supervised Injection Site in the U.S., 53 AM. J.
PREVENTIVE MED. 919, 919 (2017) ("[Safe injection sites are] legally sanctioned locations that
provide a hygienic location for individuals to inject pre-obtained drugs while observed by trained
staff. They have the dual aims of increasing the safety of individuals who inject drugs and
reducing the public nuisance [associated with public injection].").
14. See, e.g., Corey S. Davis & Derek H. Carr, The Law and Policy of Opioids for Pain
Management, Addiction Treatment, and Overdose Reversal, 14 IND. HEALTH L. REv. 1, 27-28
(2017) (examining patient access to naloxone, an opioid reversal agent).
15. See, e.g., Page M. Smith, Implementing Medicaid Health Homes to Provide
Medication Assisted Treatment to Opioid Dependent Medicaid Beneficiaries, 106 KY. L.J. 111,
133 (2017) (assessing the application of the Medicaid health home model in terms of delivering
medication assisted treatment to Medicaid recipients).
16. See, e.g., Jacob Dawson, Public Gives Input on Federal Grant to Combat Opioids in
N.H., CONCORD MONITOR (Aug. 15, 2018), https://www.concordmonitor.com/Public-gives-
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cognitive behavioral therapy tools, 7  national recovery housing best
practices," integrated treatment for individuals with concurrent mental
disorders,1 9 information sharing with families and caregivers during opioid
overdoses, 20 and even sharply-written letters by medical examiners to
prescribing physicians following a patient's death due to overdose 21 have also
received significant attention. Less attention has been paid, however, to state
benchmark health plan coverage of opioid use disorder treatments and
services.
This Article helps to fill this gap by surveying state benchmark plan
coverage of opioid use disorder treatments and services and by identifying
trends and limitations relevant thereto. This Article proceeds as follows: Part
II provides background information regarding opioid use disorder and the
treatments and services available for individuals with this disorder.22 Part III
reviews federal mental health parity law and federal mandatory mental health
and substance use disorder law as applied to insurance coverage of treatments
and services for opioid use disorder, with a focus on the Affordable Care Act's
input-to-DHHS-about-opioid-grant-fimds-19451667 (reporting public input regarding the
opioid crisis; noting public desire for better mobile services).
17. See, e.g., Press Release, Food & Drug Admin., FDA Clears Mobile Medical App to
Help Those with Opioid Use Disorder Stay in Recovery Programs (Dec. 10, 2018) ("Today, the
U.S. Food and Drug Administration cleared a mobile medical application (app) to help increase
retention (the amount of time a patient participates) in an outpatient treatment program for
individuals with opioid use disorder (OUD). The reSET-O app is a prescription cognitive
behavioral therapy intended to be used in addition to outpatient treatment under the care of a
health care professional, in conjunction with treatment that includes buprenorphine and
contingency management.").
18. See, e.g., SUPPORT for Patients and Communities Act, Pub. L. No. 115-271, § 7031
(2018) [hereinafter SUPPORT Act] ("The Secretary [of the federal Department of Health and
Human Services (Secretary)], in consultation with [other] individuals and entities . . . . shall
identify or facilitate the development of best practices, which may include model laws for
implementing suggested minimum standards for operating recovery housing.").
19. See, e.g., Allison Petersen et al., State Legislative Responses to the Opioid Crisis:
Leading Examples, 11 J. HEALTH & LIFE ScI. L. 30, 66 (2018) (discussing targeted case
management, including insurance coverage thereof, for patients with co-occurring mental health
and substance use disorders, including opioid use disorder).
20. See, e.g., SUPPORT Act, supra note 18, § 7052 ("The Secretary ... shall annually
notify health care providers regarding permitted disclosures under federal health privacy laws
during emergencies, including opioid overdoses, of certain health information to families,
caregivers, and health care providers.").
21. See, e.g., Margot Sanger-Katz, Here's a Cheap Way to Fight Drug Misuse: Send
Doctors a Sharp Letter, N.Y. TIMES (Sept. 5, 2018),
https://www.nytimes.com/2018/09/05/upshot/letters-to-doctors-opioid-research.html ("Two
studies find that nudges [sharply-written letters to [prescribing] physicians following a patient's
death from opioids] can lead to more scrupulous prescribing.").
22. Infra Part II.
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(ACA's) state benchmark health plan selection requirement and the effect on
that requirement of a recent federal district court opinion striking down the
ACA. 23 Appendix A documents state benchmark plan limitations potentially
applicable to individuals with opioid use disorder,24 and Part IV analyzes
these trends. 25 A conclusion clarifies how the invalidation of the entire ACA
could affect insurance coverage of opioid use disorder treatments and services
going forward. 26
II. BACKGROUND INFORMATION REGARDING OPIOID USE DISORDER
"Opioids include [both] prescription analgesics as well as [the] products
of the poppy plant [(Papaver somniferum)], including opium, morphine, and
codeine." 27 Although physicians prescribe opioids to relieve conditions and
symptoms such as pain, cough, and diarrhea, opioids can also produce feelings
of euphoria and tranquility that may lead some individuals to continue taking
them, notwithstanding health risks associated with opioid use and abuse.28 In
the current edition of the Diagnostic and Statistical Manual of Mental
Disorders (DSM-5), the American Psychiatric Association (APA) defines
opioid use disorder as the:
[P]roblematic pattern of opioid use leading to clinically significant
impairment or distress, as manifested by at least two of the following
[criteria], occurring within a twelve month period: (1) Opioids are
often taken in larger amounts or over a longer period of time than
intended; (2) There is a persistent desire or unsuccessful efforts to cut
down or control opioid use; (3) A great deal of time is spent in
activities necessary to obtain the opioid, use the opioid, or recover
from its effects; (4) Craving, or a strong desire to use opioids; (5)
Recurrent opioid use resulting in failure to fulfill major role
obligations at work, school or home; (6) Continued opioid use despite
having persistent or recurrent social or interpersonal problems caused
or exacerbated by the effects of opioids; (7) Important social,
occupational or recreational activities are given up or reduced
because of opioid use; (8) Recurrent opioid use in situations in which
23. Infra Part III.
24. Infra Appendix A.
25. Infra Part IV.
26. Infra Part V.
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it is physically hazardous; (9) Continued opioid use despite
knowledge of having a persistent or recurrent physical or
psychological problem that is likely to have been caused or
exacerbated by opioids; (10) Tolerance, as defined by either . .. [a]
need for markedly increased amounts of opioids to achieve
intoxication or desired effect [or] [a] markedly diminished effect with
continued use of the same amount of an opioid . . . [and] (11)
Withdrawal, as manifested by ... [t]he characteristic opioid
withdrawal syndrome . . . [or] [o]pioids (or a closely related
substance) are taken to relieve or avoid withdrawal symptoms.2 9
Individuals who exhibit two or three criteria over a twelve month period may
be diagnosed with mild opioid use disorder.30 Individuals who exhibit four or
five criteria may be diagnosed with moderate opioid use disorder and
individuals with six or more criteria may be diagnosed with severe opioid use
disorder.31 Opioid use disorder is one of several opioid-related disorders
recognized by the APA and the opioid-related disorders are one of ten sets of
substance-related disorders catalogued in the DSM-5. 32
Opioid use disorder is associated with a number of health concerns,
including lack of mucous membrane secretions, slowing of gastrointestinal
activity, impairment of visual acuity, peripheral edema, and infections such as
cellulitis, bacterial endocarditis, tuberculosis, hepatitis, and HIV. 33 Opioid use
disorder is also associated with a heightened risk for attempted or completed
suicide, as well as death due to accidental overdose, AIDS, and other medical
complications. 34 An estimated seventeen-thousand deaths each year in the
United States relate to opioid use, 35 and individuals with current or past opioid
use disorder number approximately three million in the United States and
sixteen million worldwide. 36 Opioid use disorder has a high global burden of
29. AM. PSYCHIATRIC Ass'N, DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL
DISORDERS 541 (5th ed. 2013) [hereinafter DSM-5].
30. Id. at 542.
3 1. Id.
32. The DSM-5's other substance-related disorder sets include those related to alcohol,
caffeine, cannabis, hallucinogens, inhalants, sedatives, hypnotics, anxiolytics, stimulants,
tobacco, and the other (or unknown) substance-related disorders. Id. at Table of Contents.
33. Id. at 544-45.
34. Id. at 545.
35. Schuckit, supra note 27.
36. Id.; Steven Ross Johnson, Opioid Use Disorder Cases Triple Government's Early
Estimates, MODERN HEALTHCARE (Sept. 14, 2018), https://www.modernhealthcare.com/
article/20180914/NEWS/180919929 ("As many as 6 million people in the U.S. are experiencing
opioid use disorder, nearly three times higher than the federal government's estimate of 2.1
million . . . .").
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disease; indeed, almost eleven million life-years have been lost due to opioid
use-associated health problems.3 7
Treatment of an opioid overdose may involve the administration of an
opioid reversal agent such as naloxone, which can be given through
intravenous, intramuscular, endotracheal, or subcutaneous routes.38 As
discussed in more detail in Appendix A and Part III of this Article,
approximately two-fifths of state benchmark plans do not cover any opioid
reversal agents.
Treatment of opioid use disorder also may involve medically supervised
opioid withdrawal, which is the administration of medication to an opioid-
dependent individual to reduce the severity of withdrawal symptoms that
occur when the individual stops using opioids.3 9 Withdrawal symptoms
include drug cravings, anxiety, restlessness, gastrointestinal distress,
diaphoresis, and tachycardia.40 Medications used to reduce the severity of
these symptoms include opioid agonists such as methadone, partial agonists
such as buprenorphine, mixed agonist/antagonists such as buprenorphine and
naloxone, and alpha-adrenergic agonists such as clonidine. 4 1 Opioid
withdrawal can be medically supervised in the inpatient and outpatient
settings, although inpatient supervision is associated with higher opioid
abstinence rates. 42 As discussed in more detail in Appendix A and Part III of
this Article, some state benchmark plans expressly cover these medications
while others expressly limit coverage of these medications in all or certain
settings.
37. Schuckit, supra note 27.
38. See, e.g., Shane R. Mueller et al., A Review of Opioid Overdose Prevention and
Naloxone Prescribing: Implications for Translating Community Programming into Clinical
Practice, 36 SUBSTANCE ABUSE 240, 240 (2015) ("Naloxone hydrochloride (naloxone), an
opioid antagonist, is the standard of care for treatment of opioid induced respiratory
depression.... [This review] summarized and classified existing publications on overdose
education and naloxone distribution to identify evidence of effectiveness and opportunities for
translation into conventional medical settings.").
39. See generally Anthony Plunkett et al., Opioid Maintenance, Weaning and
Detoxification Techniques: Where We Have Been, Where We Are Now and What the Future
Holds., 3 PAIN MGMT. 277, 277-84 (2013) (thoroughly discussing medically supervised opioid
withdrawal).
40. Kevin A. Sevarino, Medically Supervised Opioid Withdrawal During Treatment for
Addiction, UPTODATE, https://www.uptodate.com/contents/medically-supervised-opioid-
withdrawal-during-treatment-for-addiction (last updated Feb. 13, 2019).
41. Gavin Bart, Maintenance Medication for Opiate Addiction: The Foundation of
Recovery, 31 J. ADDICTIVE DISEASES 207, 207-13 (2012).
42. See generally Herbert D. Kleber, Pharmacological Treatments for Opioid
Dependence: Detoxification and Maintenance Options, 9 DIALOGUES IN CLINICAL
NEUROSCIENCE 455, 456 (2007) (discussing opioid withdrawal methods).
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Treatment of opioid use disorder also may include psychosocial
interventions, which are non-medical interventions that are designed to help
patients control urges to use opioids. 43 These interventions include but are
not limited to-contingency management, relapse prevention, general
cognitive behavior therapy, and treatments combining cognitive behavior
therapy and contingency management. 44 These interventions can take place
during individual, couples, family, and/or group counseling sessions, and can
occur in both the inpatient and outpatient settings, 45 including in the
psychiatric hospital, 46 substance abuse treatment facility,47 residential
treatment program, 48 partial hospitalization program, 49 intensive outpatient
treatment therapy program,50 and traditional outpatient clinic settings. Some
43. See generally Lissa Dutra et al., A Meta-Analytic Review of Psychosocial
Interventions for Substance Use Disorders, 165 AM. J. PSYCHIATRY 179, 179 (2008)
(identifying and discussing psychosocial interventions for substance use disorders).
44. Id.
45. Id
46. See ANTHEM BLUECROSS BLUESHIELD, HEALTH CERTIFICATE OF COVERAGE M-
112 (2014), https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/IN-BMP.zip
(last visited Mar. 14, 2019) (presenting Indiana benchmark plan defining a psychiatric hospital
as a facility that, for compensation, is primarily engaged in providing diagnostic and therapeutic
services for the inpatient treatment of behavioral health conditions).
47. ANTHEM BLUECROSS BLUESHIELD, BLUE CHOICE: CERTIFICATE OF COVERAGE 66
(2015), https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/2017-BMP-
SummaryME.zip (last visited Mar. 14, 2019) (presenting Maine benchmark plan defining a
substance abuse treatment facility as a residential or nonresidential institution that is licensed or
certified as a substance abuse treatment facility, that provides care to one or more patients for
alcoholism and/or drug dependency, and that is a freestanding unit or a designated unit of another
licensed health care facility).
48. See BLUE CROSS OF IDAHO, ENROLLEE CERTIFICATE 37 (2014),
https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/2017-BMPID.zip (last
visited Mar. 14, 2019) (presenting Idaho benchmark plan defining a residential treatment
program as a facility that provides long-term or severe mental disorders or substance use
disorders with residential care twenty-four hours per day).
49. See BLUECROSS BLUESHIELD OF LA., GROUP HEALTH BENEFIT PLAN: PPO GROUP
CARE 16 (2014), https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/2017-
BMP-SummaryLA-4816.zip (last visited Mar. 14, 2019) (presenting Louisiana benchmark
plan defining a partial hospitalization program (PHP) as a "structured and medically supervised
day, evening and/or night treatment program" that is provided to patients at least four hours per
day and at least three days per week; further explaining that PHP "services are of essentially the
same nature and intensity (including medical and nursing) as would be provided in a hospital"
except that the patient is in the program less than twenty-four (24) hours/day and the patient is
not considered a "resident" of the PHP).
50. See UNITEDHEALTHCARE OF KY., CERTIFICATE OF COVERAGE, RIDERS,
AMENDMENTS, AND NOTICES 65 (2013), https://www.cms.gov/CCIIO/Resources/Data-
Resources/Downloads/KY-BMP.zip (last visited Mar. 14, 2019) (presenting Kentucky
benchmark plan defining intensive outpatient treatment (IOT) as a "structured outpatient mental
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individuals with opioid use disorder also may find mutual support groups, also
known as peer-based recovery support groups and mutual aid groups, such as
Narcotics Anonymous, helpful in recovering from opioid use disorder." As
discussed in more detail in Appendix A and Part III of this Article, some state
benchmark plans expressly cover psychosocial interventions while others
expressly limit coverage of psychosocial interventions as well as mutual
support groups.
Opioid maintenance therapy is another approach to treating opioid use
disorder. Designed to "block the euphoric and sedating effects of dependent
opioids," to "relieve the cravings," and to "permit the patient to participate
[more fully] in society,"52 opioid maintenance therapy may include
methadone, buprenorphine, or naltrexone.53 When taken as directed, these
medications can be both cost effective and clinically effective in reducing
nonmedical opioid use as well as public health and safety problems relating
to opioid use, including infectious diseases, death due to overdose, and
crime. 4 As discussed in more detail in Appendix A and Part III of this Article,
some state benchmark plans expressly cover these opioid maintenance
therapies while others expressly limit their coverage.
health or substance use disorder treatment program that may be free-standing or Hospital-based
and provides services for at least three hours per day, two or more days per week").
51. See WILLIAM L. WHITE, NARCOTICS ANONYMOUS AND THE
PHARMACOTHERAPEUTIC TREATMENT OF OPIOID ADDICTION IN THE UNITED STATES 11
(2011) (discussing the perspective of Narcotics Anonymous regarding opioid addiction
treatment, including opioid maintenance therapy).
52. See generally Christie Choo, Medications Used in Opioid Maintenance Treatment,
34 U.S. PHARMACIST 40, 42 (2009) (discussing treatment options for patients on opioid
maintenance therapy); Karen Dugosh et al., A Systematic Review on the Use of Psychosocial
Interventions in Conjunction with Medications for the Treatment of Opioid Addiction, 10 J.
ADDICTION MED. 91, 91-92 (2016) (discussing medications used as part of opioid maintenance
therapy).
53. See generally AM. SOC'Y OF ADDICTION MED., ADVANCING ACCESS TO ADDICTION
MEDICATIONS: IMPLICATIONS FOR OPIOID ADDICTION TREATMENT 123 (2013) ("The three
pharmacotherapies have all shown clear clinical evidence of effectiveness in reducing opioid
use and opioid use-related symptoms of withdrawal and craving as well as risk of infectious
diseases and crime when used as part of a comprehensive treatment approach and in
appropriate doses."); M.M. Sunilkumar & Kashelle Lockman, Practical Pharmacology of
Methadone: A Long-Acting Opioid, 24 INDIAN J. PALLIATIVE CARE 10, 10 (2018) ("Methadone
is a naturally long-acting analgesic with unique pharmacodynamic and pharmacokinetic
properties compared to other opioids ... to treat severe pain.").
54. AM. SoC'Y OF ADDICTION MED., supra note 53.
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III. MENTAL HEALTH PARITY LAW & MANDATORY MENTAL HEALTH AND
SUBSTANCE USE DISORDER LAW
Historically and until quite recently both public health care programs
and private health plans distinguished between physical and mental disorders
and provided inferior insurance benefits for treatment of all mental disorders,
including opioid use disorder. For example, Medicare Part B formerly
imposed a fifty percent beneficiary coinsurance on outpatient mental health
services-including individual, family, and group psychotherapy services-
compared to the twenty percent beneficiary coinsurance traditionally applied
to outpatient non-mental health services.5 6 Many private health plans also
used to provide inferior health insurance benefits for individuals with mental
disorders by completely excluding their treatments and services from
coverage or by providing less comprehensive coverage. For example, Kaiser
Permanente's 2012 Small Group Colorado Health Benefit Plan (Kaiser Plan)
provided insurance coverage of "biologically-based mental illnesses," but the
Kaiser Plan only included six illnesses, including schizophrenia,
schizoaffective disorder, bipolar affective disorder, major depressive disorder,
specific obsessive-compulsive disorder, and panic disorder within that
55. The Author has reviewed the history of mental health insurance disparities in a
number of prior articles addressing the legal rights of individuals with gambling disorder and
other mental health conditions. See, e.g., Stacey A. Tovino, A Right to Care, 70 ALA. L. REV.
185, 211-12 (2018); Stacey A. Tovino, Dying Fast: Suicide in Individuals with Gambling
Disorder, 10 ST. Louis U. J. HEALTH L. & POL'Y 159, 159, 163-64 (2016); Stacey A. Tovino,
Gambling Disorder, Vulnerability, and the Law: Mapping the Field, 16 Hous. J. HEALTH L. &
POL'Y 101, 107-09 (2016); Stacey A. Tovino, Lost in the Shuffle: How Health and Disability
Laws Hurt Disordered Gamblers, 89 TUL. L. REV. 191, 191, 213-14 (2014). The discussion of
mental health parity law in this Part II is taken with permission, and with several recent updates
as well as technical and conforming changes, from these and the Author's other prior works in
this area.
56. See Medicare Improvements for Patients and Providers Act of 2008, Pub. L. No. 110-
275, § 102, Stat. 2494, 2498 (codified as amended at 42 U.S.C. § 13951(c)(1) (2012)) (calculating
Medicare incurred expenses as only 62.5% of the outpatient expenses associated with the
treatment of mental, psychoneurotic, and personality disorders). Until 2010, Medicare was thus
responsible for only 50% (i.e., 62.5% x 8 0%, with 80% being the Medicare approved amount)
of the cost of most outpatient mental health services, and the Medicare beneficiary was
responsible for the remaining 50%. See id. In 2008, President George W. Bush signed into law
the Medicare Improvements for Patients and Providers Act of 2008, Section 102 of which
increased Medicare's portion of incurred expenses for outpatient mental health services to
68.75% in 2010 and 2011 (resulting in a 45% beneficiary coinsurance), 75% in 2012 (resulting
in a 40% beneficiary coinsurance), 81.25% in 2013 (resulting in a 35% beneficiary coinsurance),
and 100% in 2014 and thereafter (resulting in a 20% coinsurance). See id. Since 2014, Medicare
has been paying 80% of (and Medicare beneficiaries are only paying a 20% coinsurance on) all
outpatient mental health services.
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definition.17 Neither opioid use disorder nor any other substance-related
disorder was included in that definition. Likewise, UnitedHealthcare's
traditional Certificate of Coverage provided coverage for "[b]iologically-
based [m]ental illnesses," but also defined the phrase to include
schizophrenia, bipolar disorder, pervasive developmental disorder, paranoia,
panic disorder, obsessive-compulsive disorder, and major depressive
disorder." Again, neither opioid use disorder nor any other substance-related
or addictive disorder was included in that definition.
Although many states enacted parity laws designed to put mental health
conditions on equal footing with non-mental health conditions, some of these
parity laws specifically excluded substance-related and addictive disorders
from protection as well.5 9 As an illustration, New Mexico's long-standing
parity law requires group health plans in New Mexico to provide "mental
health benefits" and to provide them at parity with "medical and surgical
benefits." 60 However, the New Mexico law specifically excludes treatments
for "substance abuse" and "chemical dependency" from the definition of
"mental health benefits." 61
During the past twenty-five years, developments in federal health
insurance law have eliminated some but not all-of these mental health
benefit disparities, including opioid use disorder benefit disparities; however,
a December 14, 2018, federal district court opinion striking down the ACA
will reverse some of these advances. As background, President Bill Clinton
signed the federal Mental Health Parity Act (MHPA) into law on September
26, 1996.62 As originally enacted, MHPA prohibited large group health plans
that offered medical and surgical benefits as well as mental health benefits
from imposing more stringent lifetime and annual spending limits on their
offered mental health benefits. 63 For example, MHPA would have prohibited
a covered large group health plan from imposing a $20,000 annual cap or a
57. KAISER PERMANENTE, 2011 COLORADO HEALTH BENEFIT PLAN DESCRIPTION
FORM: PLAN 230-CITY AND COUNTY OF DENVER-GROUP #00075 3, 6 (2006) (defining
"biologically based mental illness care").
58. See UNITEDHEALTHCARE INS. CO., CERTIFICATE OF COVERAGE 17-18, https://
www.uhc.com/content/dam/uhcdotcom/en/Legal/PDF/MY-7.pdf (last visited Mar. 14, 2019).
59. See generally Stacey A. Tovino, Reforming State Mental Health Parity Law, 11 HOU.
J. HEALTH L. & POL'Y 455, 458-59 (2011) (summarizing trends in state mental health parity
laws).
60. See N.M. STAT. ANN. § 59A-23E-18(A) (West, Westlaw through Ct. 40 of 1st Reg.
Sess. of 54th Legis. (2019)).
61. Id. § 59A-23E-18(F).
62. See Mental Health Parity Act of 1996, Pub. L. No. 104-204, 110 Stat. 2874, 2944
(codified as amended at 29 U.S.C. § 1185a (2012)).
63. Id. § 712(a)(1)-(2).
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$100,000 lifetime cap on mental health care if the plan had no annual or
lifetime caps for medical and surgical care or if the plan had higher caps-
such as a $50,000 annual cap or a $500,000 lifetime cap-for medical and
surgical care. 64
The application and scope of MHPA were very limited, however. As
originally enacted, MHPA regulated only insured and self-insured group
health plans of large employers, then defined as those employers that
employed an average of fifty-one or more employees.65 MHPA thus did not
apply to the group health plans of small employers. 66 MHPA also did not
apply to individual health plans, the Medicare Program, Medicaid non-
managed care plans, or any self-funded, nonfederal governmental plan whose
sponsor opted out of MHPA. 67 In terms of its substantive provisions, MHPA
was neither a mandated offer nor a mandated benefit law; that is, nothing in
MHPA required a large group health plan to actually offer or provide any
mental health benefits for mental health conditions such as opioid use
disorder.68 Health plans were thus free-even after the enactment of MHPA
simply not to provide any benefits for opioid use disorder or any other mental
health condition. 69 Indeed, individuals with substance use and addictive
disorders-including opioid use disorder were specifically excluded from
MHPA's modest lifetime and annual spending cap protections. 70 Finally,
MHPA did not require parity between medical and surgical benefits and
64. See id.
65. See id. § 712(c)(1)(A)-(B) (applying in each case to "a group health plan (and group
health insurance coverage offered in connection with a group health plan) for any plan of a small
employer").
66. See id. (exempting from the MHPA application group health plans of small
employers; defining small employers as those "who employed an average of at least 2 but not
more than 50 employees on business days during the preceding calendar year and who employs
at least 2 employees on the first day of the plan year").
67. See 42 U.S.C. § 300gg-21(a)(2)(A) (2012 & Supp. I 2017) (permitting sponsors of
self-insured nonfederal governmental health plans to opt out of particular federal requirements);
45 C.F.R. § 146.180(a)(1)(v) (2018) (permitting sponsors of self-insured nonfederal
governmental health plans to opt out of federal mental health parity requirements).
68. Mental Health Parity Act § 712(b)(1), 110 Stat. at 2944-45 (codified as amended at
42 U.S.C. § 300gg-26(b)(1) (2012)) ("Nothing in this section shall be construed ... as requiring
a group health plan or a health insurance issuer offering group or individual health insurance
coverage to provide any mental health or substance use disorder benefits.").
69. See id.
70. See id. §§ 712(a)(1)(B), (e)(4) ("The term 'mental health benefits' means benefits
with respect to mental health services, as defined under the terms of the plan or coverage (as the
case may be), but does not include benefits with respect to treatment of substance abuse or
chemical dependency.").
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mental health benefits in terms of deductibles, copayments, coinsurance,
inpatient day limitations, or outpatient visit limitations.7 '
Because of these limitations, President George W. Bush expanded MHPA
twelve years later by signing into law the Paul Wellstone and Pete Domenici
Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA). 72
MHPAEA built on MHPA by expressly protecting individuals with
substance-related and addictive disorders, including opioid use disorder, and
by imposing comprehensive parity requirements on large group health
plans. 73 In particular, MHPAEA provided that any financial requirements
(including deductibles, copayments, coinsurance, and other out-of-pocket
expenses) 74 and treatment limitations (including inpatient day and outpatient
visit limitations as well as non-quantitative treatment limitations such as
medical necessity requirements)75 that large group health plans imposed on
mental health and substance use disorder benefits must not have been any
more restrictive than the predominant financial requirements and treatment
limitations imposed by the plan on substantially all medical and surgical
benefits. 76 MHPAEA thus would have prohibited a large group health plan
from imposing higher deductibles, copayments, or coinsurances, or lower
inpatient day and outpatient visit maximums, on individuals seeking care for
any mental health or substance use disorder listed in the current edition of the
DSM or the World Health Organization's International Classification of
Diseases (ICD).7 7 The previous sentence is very important: if a covered large
71. See id § 712(b)(2) ("Nothing in this section shall be construed ... as affecting the
terms and conditions (including cost sharing, limits on numbers of visits or days of coverage,
and requirements relating to medical necessity) relating to the amount, duration, or scope of
mental health benefits under the plan or coverage . . . .").
72. See Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity
Act of 2008, Pub. L. No. 110-343, 122 Stat. 3881 (codified as amended at 26 U.S.C. § 9812
(2012); 29 U.S.C. § 1185a (2012); 42 U.S.C. § 300gg-26 (2012 & Supp. 1 2017)) [hereinafter
MHPAEA].
73. See id. § 512(a)(4) (adding a new definition of "substance use disorder benefits"); see
also id. § 512(a)(1) (regulating the financial requirements and treatment limitations that are
applied to both mental health and substance use disorder benefits).
74. See id § 512(a)(1) (including within the definition of "financial requirements"
"deductibles, copayments, coinsurance, and out-of-pocket expenses").
75. See id. § 512(a)(1)(B)(iii) (including within the definition of "treatment limitations"
"limits on the frequency of treatment, number of visits, days of coverage, [and] other similar
limits on the scope or duration of treatment").
76. See id. § 512(a)(1)(A)(i) (requiring both financial requirements and treatment
limitations applicable to mental health and substance use disorder benefits to be "no more
restrictive than the predominant financial requirements" and treatment limitations "applied to
substantially all [physical health benefits] covered by the plan").
77. See, e.g., Final Rules Under the Paul Wellstone and Pete Domenici Mental Health
Parity and Addiction Equity Act of 2008, 78 Fed. Reg. 68,240, 68,242 (Nov. 13, 2013) (to be
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group health plan actually offered insurance benefits for opioid use disorder,
then the DSM's and the ICD's recognition and listing of opioid use disorder
meant that the health plan would be prohibited from imposing higher financial
requirements or more stringent treatment limitations on individuals seeking
treatments and services for this condition.
Like MHPA, MHPAEA's application and scope were initially limited. As
originally enacted, MHPAEA regulated only insured and self-insured group
health plans of large employers, defined as those employers that employ an
average of fifty-one or more employees.78 MHPAEA, like MHPA, did not
apply to small group health plans, individual health plans, the Medicare
Program, Medicaid non-managed care plans, or any self-funded, nonfederal
governmental plans whose sponsors had opted out of MHPAEA. 79 In terms
of its substantive provisions, MHPAEA was neither a mandated offer nor a
mandated benefit law; that is, nothing in MHPAEA required a covered group
health plan to actually offer or provide any benefits for conditions such as
opioid use disorder. 80
codified at 45 C.F.R. pts. 146 and 147). This rule adopted the MHPAEA requirement that a
plan's definition of "mental health benefits" and "substance use disorder benefits" be "consistent
with generally recognized independent standards of current medical practice (for example, the
most current version of the Diagnostic and Statistical Manual of Mental Disorders (DSM), the
most current version of the ICD, or State guidelines)".
78. See MHPAEA, supra note 72, Pub. L. No. 110-343, 122 Stat. 3881, 3889 (codified
as amended at 26 U.S.C. § 9812(c)(1) (2012)); 29 U.S.C. § 1185a(c) (2012). See also 42 U.S.C.
§ 300gg-26 (2012 & Supp. I 2017) ("[The MHPAEA applies only to] group health plan[s] (or
health insurance coverage offered in connection with such ... plan[s]) . . . .").
79. See, e.g., CTRS. FOR MEDICARE & MEDICAID SERVS., CTR. FOR CONSUMER
OVERSIGHT & INS. OVERSIGHT, THE MENTAL HEALTH PARITY AND ADDICTION EQUITY ACT
(MHPAEA), https://www.cms.gov/cciio/programs-and-initiatives/other-insurance-protections/
mhpaea factsheet.html (last visited Jan. 14, 2019) ("MHPAEA does not apply directly to small
group health plans . . . ."). The Centers for Medicare and Medicaid Services has explained that
Medicare and Medicaid are not issuers of health insurance: "They are public health plans through
which individuals obtain health coverage. . . . However, . .. Medicaid benchmark benefit
plans .. . require compliance with certain requirements of MHPAEA." Id. "Non-Federal
governmental employers that provide self-funded group health plan coverage to their employees
(coverage that is not provided through an insurer) may elect to exempt their plan (opt-out) from
the requirements of MHPAEA . 1.4.. Id. See also Colleen L. Barry et al., A Political History of
Federal Mental Health and Addiction Insurance Parity, 88 MILBANK Q. 404, 406-07 (2010)
("[The MHPAEA] applies to Medicare Advantage coverage offered through a group health plan,
Medicaid managed care, the State Children's Health Insurance Program, and state and local
government plans," omitting Medicaid non-managed care plans).
80. See MHPAEA, supra note 72, § 512(a)(1) (regulating only those group health plans
that offer both physical health and mental health benefits); The Mental Health Parity and
Addiction Equity Act (MHPAEA), CTRS. FOR MEDICAID & MEDICARE SERVS.,
https://www.cms.gov/cciio/programs-and-initiatives/other-insurance-protections/mhpaea-fact
sheet.html (last visited Mar. 16, 2019) ("Self-insured non-Federal government employer[]"
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In late March 2010, President Obama responded to this limitation by
signing the Patient Protection and Affordable Care Act and the Health Care
and Education Reconciliation Act (HCERA) into law (as consolidated, the
Affordable Care Act (ACA))." Best known for its controversial (and now
repealed) individual health insurance mandate,8 2 the ACA had two other sets
of provisions that related to mental health parity and mandatory mental health
and substance use disorder benefits. These provisions until they were struck
down by a federal district court on December 14, 2018-improved upon some
of the limitations of MHPA and MHPAEA.
The first set of relevant ACA provisions extended MHPA's and
MHPAEA's mental health parity provisions to the individual and small group
health plans offered on and off the ACA-created health insurance
exchanges.83 After the ACA, many individual and small group health plans
that previously discriminated against individuals with opioid use disorder
through higher deductibles, copayments, and coinsurance rates-as well as
lower inpatient day and outpatient visit limitations were required to comply
with MHPA and MHPAEA.
Legislation subsequent to the ACA continued to expand and promote
compliance with MHPA and MHPAEA. For example, the 21st Century Cures
Act (hereinafter "Cures Act"), signed into law by President Obama on
December 13, 2016, required the Secretary of Health and Human Services
(HHS), the Government Accountability Office, and/or other federal agencies,
as appropriate, to issue a number of guidance documents, action plans, and
plans can opt out of the federal parity law); see also Mental Health Parity Law, TRANSAMERICA
CTR. FOR HEALTH STUDIES, https://www.transamericacenterforhealthstudies.org/health-
wellness/mental-health-guide/mental-health-parity-law (last visited Apr. 12, 2019) (The
MHPAEA's requirements do not apply to "[s]mall employer health plans" created before March
23, 2010, "[s]elf-insured non-federal government employee plans," "[c]hurch-sponsored plans,"
"[r]etiree-only plans," TriCare, Medicare, and "[t]raditional Medicaid (fee-for-service, non-
managed care)").
81. See Patient Protection and Affordable Care Act, Pub. L. No. 111-148, 124 Stat. 119
(2010) (codified as amended in scattered sections of 26 and 42 U.S.C.).
82. Id. § 5000A(a), 124 Stat. at 244. This law added the following to the Internal Revenue
Code: "An applicable individual shall for each month beginning after 2013 ensure that the
individual, and any dependent of the individual who is an applicable individual, is covered under
minimum essential coverage for such month." Id
83. Id. § 13110) ("[MHPAEA] shall apply to qualified health plans in the same manner
and to the same extent as such section applies to health insurance issuers and group health
plans."). See also id § 1562(c)(4) (identifying the conforming and technical changes that will
be made to former 42 U.S.C. 300gg-5, now codified at 42 U.S.C. § 300gg-26); CTR. FOR
CONSUMER INFO. & INS. OVERSIGHT, ESSENTIAL HEALTH BENEFITS BULLETIN 12 (2011)
("The Affordable Care Act also specifically extends MHPAEA to the individual market.").
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reports addressing compliance with MHPA and MHPAEA.84 By further
example, the SUPPORT Act, signed into law by President Trump on October
24, 2018, required the Children's Health Insurance Program (CHIP) to
comply with MHPA and MHPAEA.8 "
On December 14, 2018, however, the United States District Court for the
Northem District of Texas struck down the entire Affordable Care Act,8 6
including the ACA provisions extending MHPA's and MHPAEA's mental
health parity provisions to the individual and small group health plans offered
on and off the ACA-created health insurance exchanges. To the extent that
this District Court opinion (hereinafter "District Court Opinion") stands, the
ACA's extension of mental health parity to individual and small group health
plans is no longer valid.
The second set of relevant ACA provisions required certain health plans
to actually provide mental health and substance use disorder benefits. That is,
the ACA required individual and small group health plans, 7 exchange-
offered qualified health plans," state basic health plans,8 9 and Medicaid
benchmark plans90 to offer "[m]ental health and substance use disorder
services, including behavioral health treatment" in addition to nine other
categories of essential health benefits (EHBs). 91 Even before the District
Court Opinion, not every individual with health insurance benefited from
these ten required EHB categories because some health plans, including self-
insured health plans and grandfathered health plans, were exempt from the
requirement to provide the ten EHBs. 92 In some states, such as Nevada, only
84. 21st Century Cures Act, Pub. L. No. 114-255, § 13001, 130 Stat. 1033, 1278 (2016);
id. § 13002, 130 Stat. at 1283 (requiring an action plan); id § 13004, 130 Stat. at 1286 (requiring
a Government Accountability Office report).
85. SUPPORT for Patients and Communities Act, H.R. 6, 115th Cong. § 5021 (2018).
86. See Texas v. United States, 340 F. Supp. 3d 579, 618-19 (N.D. Tex. 2018) (declaring
the ACA's individual mandate unconstitutional and further declaring the remaining provisions
of the ACA "inseverable" and therefore "invalid"); see id at 615 ("In sum, the Individual
Mandate 'is so interwoven with [the ACA's] regulations that they cannot be separated. None of
them can stand."' (internal citations omitted)).
87. See Patient Protection and Affordable Care Act, § 1201(2)(A) (codified at 42 U.S.C.
§ 300gg-6(a) (2012)).
88. See id. § 1301(a)(1)(B) (adding new 42 U.S.C. § 18021(a)(1)(B) (2012)).
89. Individuals eligible for state basic health plan coverage include individuals who are
not eligible for Medicaid and whose household income falls between 133% and 200% of the
federal poverty line for the family involved. Id. § 133 1(e)(1)(B).
90. Id. § 2001(c)(3) (adding new 42 U.S.C. § 1396u-7(b)(5)-(6) (2012)).
91. Id. § 1302(b)(1)(A)-(J).
92. See Interim Final Rules for Group Health Plans and Health Insurance Coverage
Relating to Status as a Grandfathered Health Plan Under the Patient Protection and Affordable
Care Act, 75 Fed. Reg. 34,538, 34,562 (June 17, 2010) (codified at 29 C.F.R. § 2590 (2013))
(adopting 29 C.F.R. § 2590.715-1251(a), which defines "[g]randfathered health plan coverage"
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a small percentage of state residents were covered by a health plan that was
required to comply with the ACA's EHB mandate, leaving the vast majority
of residents without federally-mandated mental health and substance use
disorder benefits post-ACA but pre-District Court Opinion. 9
For those health plans that were required by the ACA to provide benefits
within the ten EHB categories, the ACA's statutory EHB requirements were
unclear as to whether particular benefits-such as opioid use disorder
benefits were included. As a result, HHS issued its first set of final
regulations implementing the ACA's EHB requirements on February 25, 2013
(2013 Final Regulations). 94 The 2013 Final Regulations required states to
select (or be defaulted into) a benchmark plan95 that was sold in 2012 and that
provided coverage for the ten EHB categories, including mental health and
substance use disorder services, 96 and that served as a reference plan for health
plans in each state. According to the 2013 Final Regulations, health plans in
the state to which the EHB requirements applied were required to provide
health benefits "substantially equal" to those provided by the state's
benchmark plan, including the benchmark plan's covered benefits and
excluded benefits. 97 Thus, the question of whether (and the extent to which) a
particular health insurance policy or plan was responsible for providing
(between years 2014 and 2016) benefits for a particular mental disorder-
as "coverage provided by a group health plan, or a health insurance issuer, in which an individual
was enrolled on March 23, 2010"); id. at 34,559 (explaining that Public Health Service Act
§ 2707 does not apply to grandfathered health plans); id. at 34,567-68 (adopting 29 C.F.R.
§ 2590.715-1251(c)(1), which states that "the provisions of PHS Act section[] ... 2707 . . .do
not apply to grandfathered health plans"); U.S. DEP'T LABOR, APPLICATION OF THE NEW
HEALTH REFORM PROVISIONS OF PART A OF TITLE XXVII OF THE PHS ACT TO
GRANDFATHERED PLANS 1 (2010) (explaining that ACA's essential benefit package
requirement is not applicable to grandfathered plans); INST. OF MED., ESSENTIAL HEALTH
BENEFITS: BALANCING COVERAGE AND COST 19 (2012) (listing the health plan settings to
which ACA's EHB requirement do not apply); COMMONWEALTH FUND, THE ESSENTIAL
HEALTH BENEFITS PROVISIONS OF THE AFFORDABLE CARE ACT: IMPLICATIONS FOR PEOPLE
WITH DISABILITIES 3 (2011) ("The act exempts large-group health plans, as well as self-insured
[Employee Retirement Income Security Act] plans and ERISA-governed multiemployer welfare
arrangements not subject to state insurance law, from the essential benefit requirements.").
93. See e-mail from Glenn Shippey, Nev. Div. of Ins., to Author (Apr. 8, 2016, 3:33 PM
PT) (on file with author) ("Please note that fewer than 10% of Nevadans are covered under an
individual or small group policy in the state, and large employers are not required to provide
coverage for essential health benefits.") [hereinafter Shippey E-mail].
94. Patient Protection and Affordable Care Act; Standards Related to Essential Health
Benefits, Actuarial Value, and Accreditation, 78 Fed. Reg. 12,834 (Feb. 25, 2013) (to be codified
at 45 C.F.R. pts. 147, 155, and 156).
95. Id at 12,866 (adopting 45 C.F.R. § 156.100).
96. Id. (adopting 45 C.F.R. § 156.1 10(a)(5)).
97. Id. at 12,867 (adopting 45 C.F.R. § 156.115(a)).
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such as opioid use disorder-required an analysis of the applicability of the
ACA's EHB provision to the policy or plan as well as the content of the state's
selected benchmark plan.
The State of Nevada's First Benchmark Plan can be used to illustrate the
application of these rules. Nevada's first benchmark plan was the Health Plan
of Nevada Point of Service Group 1 C XV 500 HCR Plan (Nevada's First
Benchmark Plan).9 8 If Nevada's First Benchmark Plan included opioid use
disorder benefits, then individual, small group, and other ACA-covered health
plans in Nevada were responsible for providing these benefits in years 2014,
2015, and 2016.99 On the other hand, if Nevada's First Benchmark Plan did
not include opioid use disorder benefits on March 31, 2012, then benefits for
this disorder were not considered EHBs in Nevada, and individuals with
opioid use disorder did not have coverage in years 2014, 2015, and 2016
unless their health plans voluntarily included such benefits'00 or unless they
accessed separate state funds (only available in some states) for relevant
treatments and services. 101
Nevada's First Benchmark Plan included coverage of both inpatient and
outpatient services for substance abuse disorder, without limitation. 102
Because opioid use disorder is one type of substance abuse disorder, Nevada's
First Benchmark Plan thus required health plans that were required to comply
with the ACA's EHB requirements to provide coverage for medically
necessary inpatient and outpatient treatments for opioid use disorder in years
2014, 2015, and 2016.
In regulations published on February 27, 2015 (the 2015 Final
Regulations), HHS required states to select a new benchmark plan that was
sold in 2014 and that would be effective for years 2017, 2018, and 2019
(Second Benchmark Plan).1 03 The deadline for states to select that Second
98. CTRS. FOR MEDICARE & MEDICAID SERVS., NEVADA EHB BENCHMARK PLAN 1,
https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/Updated-Nevada-Bench
mark-Summary.pdf (last visited Mar. 14, 2019).
99. See Shippey E-mail, supra note 93 (explaining the application of the EHB
requirements in the State of Nevada).
100. See AMANDA CASSIDY, STATES HAVE DETERMINED THE MINIMUM SET OF
BENEFITS TO BE INCLUDED IN INDIVIDUAL AND SMALL-GROUP INSURANCE PLANS. WHAT'S
NEXT? 2 (2013) ("HHS has indicated that [the benchmark plan] approach may be changed in
2016 and in future years based on evaluation and feedback.").
101. Cf SARAH A. ST. JOHN ET AL., UNLV CTR. FOR DEMOCRATIC CULTURE, PROBLEM
GAMBLING AND TREATMENT IN NEVADA (Dmitri N. Shalin ed., 2012) (discussing problem
gambling treatments that are partially or fully supported by the State of Nevada).
102. CTRS. FOR MEDICARE & MEDICAID SERVS., supra note 98, at 3.
103. See, e.g., Patient Protection and Affordable Care Act; HHS Notice of Benefit and
Payment Parameters for 2016, 80 Fed. Reg. 10,750, 10,812 (Feb. 27, 2015).
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Benchmark Plan was June 1, 2015.104 Nevada, for example, selected the
Health Plan of Nevada Solutions Health Maintenance Organization Platinum
15/0/90% Plan. 0 5 Nevada's Second Benchmark Plan again covered inpatient
and outpatient services for "substance abuse disorder," including opioid use
disorder, although the Second Benchmark Plan set forth two limitations on
such coverage.1 06 First, the plan required prior authorization for all "non-
routine" outpatient substance abuse treatments. 0 7 Second, the plan required
prior authorization for all "inpatient" substance abuse treatment as well. 0
On April 17, 2018, HHS published a third rule on this topic (the 2018
Final Regulations) giving states the option to select a new (i.e., third)
benchmark plan that would become effective in the year 2020. However, the
2018 Final Regulations took a slightly different approach compared to the
2013 and 2015 Final Regulations.' 09 In particular, the 2018 Final Regulations
gave each state the flexibility to change the state's second benchmark plan by:
(1) selecting another state's second benchmark plan; (2) replacing one or more
categories of the state's current EHBs with the same category or categories of
EHBs set forth in another state's second benchmark plan; or (3) selecting an
entirely new benchmark plan so long as the new benchmark plan did not
exceed the generosity of the most generous among a set of comparison plans,
including the state's second benchmark plan and any of the state's options for
a second benchmark plan.11 0 State selections were due July 2, 2018.'
Interestingly, only one state (Illinois) selected a new (i.e., third) benchmark
104. See, e.g., Essential Health Benefits, NEV. DIv. OF INS., DEP'T Bus. & INDUS.,
http://doi.nv.gov/Healthcare-Reform/Individuals-Families/Essential-Health-Benefits (last
visited Nov. 2, 2018) (identifying Nevada's benchmark plan selections); JoAnn Volk, States
Need to Select Essential Health Benefit Benchmark Plans for 2017 Soon!, GEO. U. HEALTH
POL'Y INST., CTR. FOR CHILDREN & FAMILIES (May 7, 2015),
https://ccf georgetown.edu/2015/05/07/states-need-select-essential-health-benefit-benchmark-
plans-2017-soon (referencing the June 1, 2015 deadline for states to select an EHB benchmark
for small employer and individual coverage available in 2017).
105. CTRS. FOR MEDICARE & MEDICAID SERVS., NEVADA 2017 EHB BENCHMARK PLAN
1 (2017), https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/NV-BMP.zip
(last visited Mar. 14, 2018).
106. Id. at 3.
107. Id.
108. Id.
109. See generally Patient Protection and Affordable Care Act; HHS Notice of Benefit and
Payment Parameters for 2019, 83 Fed. Reg. 16,930 (Apr. 17, 2018) (to be codified at 45 C.F.R.
pt. 147, 153-58).
110. Id. at 17,068 (creating new 45 C.F.R. § 156.111(a)).
111. Id. at 17,020.
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plan as permitted by the 2018 Final Regulations." 2 All of the other states kept
their second benchmark plans, which will now remain in effect through the
end of year 2020, pending, of course, the outcome of any appeals of the
District Court Opinion. 113
To the extent the District Court Opinion is affirmed, the ACA's EHB and
benchmark selection requirements will fall. Remember, however, that the
second benchmark plans were selected by states from preexisting health
insurance plans that were already being sold in each state independent of the
ACA. Plans like these will continue to be sold post-District Court Opinion.
Therefore, these benchmark plans are helpful for understanding current and
typical coverage of treatments and services for opioid use disorder. To this
end, Appendix A and Part III below survey all current benchmark plans,
including the second benchmark plans of all fifty states and the District of
Columbia, as well as the third benchmark plan of Illinois. As discussed in
more detail below, these benchmark plans demonstrate substantial variation
in terms of their opioid use disorder coverage and limitations.
IV. DISCUSSION OF STATE BENCHMARK PLANS
A. Only One State Took Advantage of the Opportunity Which the 2018
Final Regulations Presented to Improve Opioid Use Disorder
Coverage
At the outset, it is important to note that only one state-Illinois-took
advantage of the opportunity presented by the 2018 Final Regulations" 4 to
select anew benchmark plan that would improve insurance coverage of opioid
use disorder treatments and services in that state. As discussed in Part II, all
fifty states and the District of Columbia had the opportunity to change their
second benchmark plans by: (1) selecting another state's second benchmark
plan; (2) replacing one or more categories of the state's current EHBs with the
same category or categories of EHBs set forth in another state's second
benchmark plan; or (3) selecting an entirely new benchmark plan so long as
112. THE ACCESS TO CARE AND TREATMENT (ACT) PLAN 2,
https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/2020-BPM-IL.zip
[hereinafter Illinois Third Benchmark Plan] (last visited Mar. 14, 2019).
113. See Texas v. United States, 340 F. Supp. 3d 579, 615 (Dec. 14, 2018) ("In sum, the
Individual Mandate 'is so interwoven with [the ACA's] regulations that they cannot be
separated. None of them can stand."' (internal citations omitted)); id. at 619 (declaring the
ACA's individual mandate unconstitutional; further declaring the remaining provisions of the
ACA "inseverable" and therefore "invalid").
114. See generally Patient Protection and Affordable Care Act; HHS Notice of Benefit and
Payment Parameters for 2019, 83 Fed. Reg. 16,930 (Apr. 17, 2018).
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the new benchmark plan did not exceed the generosity of the most generous
among a set of comparison plans, including the state's second benchmark plan
and any of the state's options for a second benchmark plan." 5 This
opportunity was open through July 2, 2018.116 Illinois selected an entirely new
benchmark plan (The Illinois Access to Care and Treatment (ACT) Plan) in
accordance with the third option made available by the 2018 Final
Regulations. 117
The ACT Plan contains four new opioid-related provisions. First, it
covers "at least one intranasal opioid reversal agent prescription for initial
prescriptions of opioids with dosages of 50 MME or higher."" In contrast,
Illinois' Second Benchmark Plan covered zero (or no) opioid reversal
agents.11 9 Second, the ACT Plan removes barriers to the prescription of
medication-assisted treatment (MAT) of opioid use disorder by removing
prior authorization requirements, dispensing limits, first-fail policies, and
lifetime limit requirements otherwise applicable to MAT of opioid use
disorder.1 20 Third, the ACT Plan covers tele-psychiatry, including for opioid
use disorder.12' Finally, the ACT Plan limits opioid prescriptions for acute
pain to no more than seven days.1 22 Although Illinois was the only state to
take advantage of the opportunity to incorporate opioid-specific provisions
the state believed would help combat the opioid crisis, the District Court
Opinion striking down of the ACA if affirmed will neutralize the impact
of this missed opportunity in other states.1 23
115. Id. at 17,068 (creating new 45 C.F.R. § 156.111(a)).
116. Id. at 17,020.
117. Illinois Third Benchmark Plan, supra note 112.
118. Id. at 32.
119. BLUECROSS BLUE SHIELD OF ILL., ILLINOIS EHB BENCHMARK PLAN 5,
https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/IL-BMP.zip (last visited
Mar. 14, 2018) (showing that Illinois' Second Benchmark Plan included coverage of zero (0)
opioid reversal agents) [hereinafter Illinois Second Benchmark Plan].
120. Illinois Third Benchmark Plan, supra note 112, at 21 ("Benefits for Buprenorphine
products or brand equivalent products for medically assisted treatment (MAT) of opioid use
disorder shall not include prior authorization, dispensing limits, fail first policies, or lifetime
limit requirements.").
12 1. Id. at 11 ("Benefits are available when ... you utilize telepsychiatry care (care may
be provided by either a prescriber or licensed therapist).").
122. Id. at 31 ("Short-term opioid prescriptions for acute pain will be provided for no more
than 7 days.").
123. See infra Part V.
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B. Many State Benchmark Plans Provide Comprehensive Substance Use
Disorder Benefits
At the outset, it is also important to note that many state benchmark
plans-as currently written-contain comprehensive mental health and
substance use disorder benefits that: (1) can be accessed by individuals with
opioid use disorder; and (2) contain no limitations other than those that apply
equally to physical health benefits. Missouri's Second Benchmark Plan, for
example, covers a wide variety of mental health and substance use disorder
services, including: (1) inpatient services delivered in a hospital or other
inpatient facility, including "psychotherapy, psychological testing, convulsive
therapy, detoxification, and rehabilitation"; (2) outpatient services delivered
in an outpatient department of a hospital as well as during an outpatient office
visit; (3) day treatment services, defined as those services that are "more
intensive than outpatient visits but less intensive than an overnight stay in [a]
[h]ospital"; and (4) residential treatment services, defined as specialized
twenty-four-hour treatment services provided in a licensed residential
treatment center or intermediate care facility, including observation and
assessment by a psychiatrist, rehabilitation, therapy, education, recreational,
and social activities.1 24 These covered services may be provided by a
psychiatrist, psychologist, neuropsychologist, licensed clinical social worker,
mental health clinical nurse specialist, licensed marriage and family therapist,
or licensed professional counselor.1 25  Although Missouri's Second
Benchmark Plan does impose a thirty percent coinsurance on in-network
substance use disorder care and a fifty percent coinsurance on out-of-network
substance use disorder care,1 26 the plan imposes the same coinsurance
percentages on non-mental health and non-substance use disorder care,1 27 thus
raising no issues under the financial requirement provisions set forth in federal
mental health parity law, as discussed in Part II.128
The same is true of many other state benchmark plans as well. Virginia's
Second Benchmark Plan covers: (1) "[i]npatient [s]ervices in a hospital or
other facility," including "individual psychotherapy, group psychotherapy,
psychological testing, counseling with family members to assist with the
patient's diagnosis and treatment, convulsive therapy, detoxification, and
124. ANTHEM BLUECROSS BLUESHIELD, CERTIFICATE OF COVERAGE: SILVER
DIRECTACCESS PLUS 50 (2015), https://downloads.cms.gov/cciio/20170%`2OBenchmark%/
20SummaryMO revised% 20508.zip (last visited Mar. 14, 2019).
125. Id. at 50-51.
126. Id. at 16.
127. See supra note 124 and accompanying text.
128. Id. at 15.
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rehabilitation"; (2) "[o]utpatient [s]ervices consisting of treatment in an
outpatient department of a [h]ospital and office visits," including "individual
psychotherapy, group psychotherapy, psychological testing and medication
management visits"; (3) partial day services; and (4) residential treatment
facility services, including "observation and assessment by a psychiatrist" as
well as "rehabilitation, therapy, education, and recreational or social
activities."129 Virginia's Second Benchmark Plan covers these services
regardless of whether they are provided by a psychiatrist, psychologist,
neuropsychologist, licensed clinical social worker, mental health clinical
nurse specialist, licensed marriage and family therapist, or licensed
professional counselor.1 30 Although Virginia's Second Benchmark Plan does
impose a $500 copayment per day up to a maximum of $1,500 per
admission-on inpatient substance use disorder care,131 Virginia imposes the
same copayments on inpatient care for physical health conditions.1 32 The
copayments thus do not violate federal mental health parity law, as discussed
in Part II, although they may raise an issue regarding the association between
cost and access to inpatient substance use disorder care. 133 Because plans like
the Missouri and Virginia plans will continue to be sold even if the District
Court Opinion is affirmed, some insureds will continue to benefit from
comprehensive mental health and substance use disorder benefits.
C. Some State Benchmark Plans Expressly Acknowledge and/or Require
Compliance with Mental Health Parity Laws
Some state benchmark plans expressly acknowledge the concept of
mental health parity and/or expressly require compliance with mental health
parity laws-in particular with inpatient, outpatient, or prescription drug
129. ANTHEM BLUECROSS BLUESHIELD, CERTIFICATE OF COVERAGE: ANTHEM
PREMIER DIRECTACCESS 47 (2014), https://downloads.cms.gov/cciio/BMP%/
20SummaryVA.zip (last visited Mar. 14, 2019).
130. Id. at 47-48.
131. Id. at 19.
132. Id. at 18.
133. Many state benchmark plans impose considerable copayments or coinsurance
amounts on substance use disorder care. For example, California's Second Benchmark Plan
applies a $400 per day copayment on inpatient mental health care services, including inpatient
detoxification services. However, California's Second Benchmark Plan applies the same $400
per day copayment on inpatient non-mental health care. See KAISER FOUND. HEALTH PLAN,
KAISER PERMANENTE FOR SMALL BUSINESSES: $30 COPAYMENT PLAN 1-2 (2014),
https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/2017-BMP_CA.zip (last
visited Mar. 14, 2019). The high copayments and coinsurance amounts applicable to substance
use disorder care thus do not violate mental health parity law although they raise an issue
regarding the association between cost-sharing, access to health care, and health itself.
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contexts. For example, Idaho's Second Benchmark Plan states the following
with respect to coverage of inpatient care: "The benefits provided for
[i]npatient hospital services and [i]npatient medical services in this section are
also provided for the care of [m]ental or [n]ervous [c]onditions, [a]lcoholism,
[s]ubstance [a]buse or [a]ddiction, or any combination of these."1 34 Idaho's
Second Benchmark Plan contains a parallel statement in the context of
outpatient care coverage: "The benefits provided for [o]utpatient [h]ospital
[s]ervices and [o]utpatient [m]edical [s]ervices in this section are also
provided for [m]ental or [n]ervous [c]onditions, [a]lcoholism, [s]ubstance
[a]buse or [a]ddiction, or any combination of these."1 35 Kansas' Second
Benchmark Plan contains a parallel statement in the context of prescription
drug coverage: "Psychotherapeutic drugs used for the treatment of [m]ental
[i]llness and [s]ubstance [u]se [d]isorders [are covered] under terms and
conditions not less favorable than coverage provided for other Prescription
Drugs."1 36
Some state benchmark plans expressly acknowledge the concept of
mental health parity and/or expressly require compliance with mental health
parity laws in all contexts without specifying application to the inpatient,
outpatient, or prescription drug contexts. For example, Massachusetts' Second
Benchmark Plan states: "The financial requirements and treatment limits for
your mental health or substance abuse coverage can be no more restrictive
than those for your medical and surgical coverage."1 37 Similarly, the New
Jersey Benchmark Plan states: "Horizon BCBSNJ [(Blue Cross Blue Shield
of New Jersey)] pays benefits for the [c]overed [c]harges a [c]overed [p]erson
incurs for the treatment of [m]ental [i]llness or [s]ubstance [a]buse the same
way Horizon BCBSNJ would for any other Illness, if such treatment is
prescribed by a [p]ractitioner."1 38 Likewise, the Indiana Benchmark Plan
states: "Coverage for the treatment of behavioral health and substance abuse
conditions is provided in compliance with state and federal law."1 39 The
134. BLUE CROSS OF IDAHO, supra note 48, at 10.
135. Id.
136. BLUE CROSS BLUE SHIELD OF KAN., COMPREHENSIVE MAJOR MEDICAL: GROUP
CERTIFICATE 29 (2014), https://www.cms.gov/CCIIO/Resources/Data-
Resources/Downloads/2017-BMP-SummaryKS-4 816.zip (last visited Mar. 14, 2019).
137. BLUE CROSS BLUE SHIELD OF MASS., HMO BLUE NEW ENGLAND: $2,000
DEDUCTIBLE 5 (2014), https://www.cms.gov/CCIIO/Resources/Data-
Resources/Downloads/2017-BMP-SummaryMA_4816.zip (last visited Mar. 14, 2019).
138. HORIZON BLUE CROSS BLUE SHIELD OF N.J., SMALL GROUP HEALTH CARE
BENEFITS POLICY 63 (2014), https://downloads.cms.gov/cciio/bmp-summary-nj.zip (last visited
Mar. 14, 2019).
139. ANTHEM BLUECROSS BLUESHIELD, supra note 46, at M-13, M-24-25. See also
UNITEDHEALTHCARE OF KY., supra note 50, at II ("Benefits for mental health conditions and
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Montana Benchmark Plan is very succinct in this respect: "Benefits for
[c]hemical [d]ependency will be paid as any other Illness."1 40
On the other hand, some benchmark plans contain no provisions requiring
compliance with mental health parity law. For example, the Second
Benchmark Plans of Alabama,141 the District of Columbia,1 42 Georgia,1 43 and
Wyoming 44 contain no provisions requiring compliance with state and/or
federal mental health parity law.
D. Prior Authorization Is the Most Common Substance Use Disorder
Coverage Limitation
Prior authorization (also called with slight variation in meaning prior
certification, prior approval, or prior review [hereinafter prior authorization])
is the most common substance use disorder coverage limitation. That is, many
state benchmark plans require an insured to request and obtain prior
authorization for outpatient, inpatient, and/or other substance use disorder
services from the individual's health plan. Without such prior authorization,
substance use disorder coverage may be denied, limited, or delayed. The
twenty-eight states that contain some type of prior authorization requirement
potentially applicable to substance use disorder care-including opioid use
disorder care-include Arizona, Arkansas, Colorado, Connecticut, the
District of Columbia, Florida, Hawaii, Idaho, Illinois (Second Benchmark
Plan only), Louisiana, Maine, Maryland, Massachusetts, Michigan,
Mississippi, Nebraska, Nevada, North Carolina, North Dakota, Oklahoma,
Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Vermont, and
substance use disorder conditions that are [c]overed [h]ealth [s]ervices under the [p]olicy must
be treated in the same manner and provided at the same level as [c]overed [h]ealth [s]ervices for
the treatment of other [s]ickness or [i]njury.").
140. BLUECROSS BLUESHIELD OF MONT., BLUE PREFERRED GOLD PPO 007 at 33 (2014),
https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/2017-BMP_MT.zip (last
visited Mar. 14, 2019).
141. See BLUE CROSS BLUE SHIELD OF ALA., 320 PLAN (2017),
https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/2017-BMP-
SummaryAL-4816.zip (last visited Mar. 14, 2019).
142. See GROUP HOSPITALIZATION AND MED. SERVS., BLUE PREFERRED PPO $1,000 -
100%/80% (2014), https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/BMP-
SummaryDC-4816.zip (last visited Mar. 14, 2019).
143. See HUMANA EMP. HEALTH PLAN OF GA., CERTIFICATE OF COVERAGE,
https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/GA-BMP.zip (last visited
Mar. 14, 2019).
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Wisconsin. 145 These prior authorization requirements are described in more
detail at Appendix A.1 46 Connecticut's Second Benchmark Plan is noteworthy
because its prior authorization requirement applies only to "outpatient
treatment of opioid dependence," but not to outpatient treatment of any other
substance use disorder.147 Why the Connecticut Plan singles out opioid use
disorder but not other substance use disorders-for prior authorization is
unclear. Whether these prior authorization requirements violate mental health
parity law depends on whether they are enforced and whether parallel prior
authorization requirements exist in the context of offered non-mental health
benefits. 148
E. Many Benchmark Plans Cover No Opioid Reversal Agents
The ACA requires each state benchmark plan to list the number of
covered drugs in each United States Pharmacopeia (USP) category and
class.1 49 USP categories relevant to opioids and opioid use disorder include
analgesics and anti-addiction agents.5 0 Within the analgesics category,
classes relevant to opioids include long-acting analgesics and short-acting
analgesics."' Within the anti-addiction agent category, classes relevant to
opioid use disorder include opioid dependence treatments and opioid reversal
agents. 5 2 Although there is substantial variation among benchmark plans, a
review of Appendix A shows that many state benchmark plans cover
approximately the following number of drugs in each relevant USP categories
145. See infra Appendix A (summarizing relevant prior authorization requirements in the
third column).
146. See infra Appendix A.
147. CONNECTICARE INS. CO., CONNECTICARE FLEX POS PLAN 82 (2014),
https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/CT-BMP.zip (last visited
Mar. 14, 2019).
148. See U.S. DEP'T HEALTH & HUMAN SERVS., WARNING SIGNS- PLAN OR POLICY NON-
QUANTITATIVE TREATMENT LIMITATIONS (NQTLS) THAT REQUIRE ADDITIONAL ANALYSIS
To DETERMINE MENTAL HEALTH PARITY COMPLIANCE 2 (explaining that this analysis is
required); Also noting that prior authorization requirements applicable to mental health care can
serve as a "red flag" that a plan or issuer may be imposing an impermissible non-quantitative
treatment limitation (NQTL) on mental health care and that: "Further review of the processes,
strategies, evidentiary standards, or other factors used in applying the NQTL to both [mental
health and substance use disorder] and med/surg benefits will be required to determine parity
compliance. Note that these plan/policy terms do not automatically violate the law, but the plan
or issuer will need to provide evidence to substantiate compliance.". Id. at 2.
149. See infra Appendix A (listing categories and classes relevant to opioids and opioid
use disorder for all states and the District of Columbia).
150. See infra Appendix A.
151. See infra Appendix A.
152. See infra Appendix A.
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and classes: (1) ten long-acting opioid analgesics; (2) twelve short-acting
opioid analgesics; (3) two opioid dependence treatments; and (4) one opioid
reversal agent. 153
That said, the Second Benchmark Plans of the following twenty states, as
written, cover zero (i.e., no) opioid reversal agents: Alabama, Alaska,
Arkansas, Florida, Hawaii, Illinois, Iowa, Louisiana, Michigan, Minnesota,
Mississippi, New Mexico, New York, North Carolina, Oklahoma,
Pennsylvania, Tennessee, Texas, Utah, and Wisconsin. 5 4 If a state
benchmark plan covers zero drugs within a particular USP class, such as the
opioid reversal agent class, regulations implementing the ACA require plans
that must comply with the ACA's EHB provision to disregard the benchmark
plan's zero coverage and to cover at least one drug per USP class.' 5 Before
the District Court Opinion, then, plans required to comply with the EHB
provision were required to cover at least one opioid reversal agent. However,
when the District Court Opinion struck down the ACA, it struck down the
EHB provision within the ACA. The result is that, if the District Court
Opinion is affirmed, health plans in all states may permissibly cover zero
opioid reversal agents unless some other non-ACA law such as a state
mandated benefit law requires coverage of one or more opioid reversal
agents.
It is noteworthy that the Third Benchmark Plan selected by Illinois, which
would be effective in 2020, does cover one opioid reversal agent. 5 6 As noted
above, Illinois' Second Benchmark Plan covered zero opioid reversal
agents. ' 7 Illinois may have made this change to respond to the opioid crisis.
That said, if the District Court Opinion is affirmed, health plans in Illinois
could revert to covering zero opioid reversal agents.
153. BLUECROSS BLUESHIELD OF MONT., MONTANA 2017 EHB BENCHMARK PLAN 1,
https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/2017-BMP_MT.zip (last
visited Mar. 14, 2019) (covering this typical number of drugs in each category and class).
154. See infra Appendix A.
155. 45 C.F.R. § 156.122(a)(1) (2018) ("A health plan does not provide essential health
benefits unless it: (1) Subject to the exception in paragraph (b) of this section, covers at least the
greater of: (i) One drug in every United States Pharmacopeia (USP) category and class; or (ii)
The same number of prescription drugs in each category and class as the EHB-benchmark
plan.").
156. See Illinois Third Benchmark Plan, supra note 112, at 7,
https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/2020-BPM-IL.zip (last
visited Mar. 14, 2019).
157. See Illinois Second Benchmark Plan, supra note 119.
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F. Some State Benchmark Plans Limit Coverage of Residential
Treatment Facility Care
Some state benchmark plans expressly cover services provided to
individuals with substance use disorders in a residential treatment facility.1'
Other state benchmark plans expressly exclude from coverage: (1) services
provided to individuals with mental health conditions in general (or substance
use disorders in particular) in a residential treatment facility, and/or (2)
residential treatment services provided in another facility, such as a chemical
dependency facility. Illustrative plans with exclusions include the Second
Benchmark Plans of Alabama, 5 9 Florida,1 60 Michigan,161 Minnesota,1 62
158. See CAREFIRST BLUECHOICE, BLUECHOICE HMO HSA-HRA $1,500 at B30 (2014),
https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/MD-BMP.zip (last visited
Mar. 14, 2019).
159. BLUECROSS BLUESHIELD OF ALA., supra note 141, at 15-16.
160. BLUE CROSS BLUE SHIELD OF FLA., BLUEOPTIONS: SMALL EMPLOYER MASTER
POLICY HEALTH CARE REFORM ENDORSEMENT 1-2 (2014),
https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/2017-BMP-
SummaryFL-4816.zip (last visited Mar. 14, 2019).
161. PRIORITYHEALTH, PRIORITYHMO 26 (2014),
https://downloads.cms.gov/files/CCIIO/2017_benchmarksummarymi_0331 17.zip (last
visited Mar. 14, 2019) (excluding services provided in a "residential" facility).
162. HEALTHPARTNERS, FOR SMALL EMPLOYERS BENEFITS CHART 8 (2014),
https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/2017-BMP-




Nebraska,' 63 North Dakota,' 64 Rhode Island,1 65 South Carolina,1 66 Texas, 167
and Utah.168
Other state benchmark plans limit, but do not completely exclude form
coverage, substance use disorder care provided in a residential treatment
facility. For example, Iowa's Second Benchmark Plan covers services
provided for chemical dependency in a residential treatment facility, but only
when such services are provided "on an intensive outpatient basis, or for
partial hospitalization treatment, or for treatment that is provided as an
inpatient at an acute level of care requiring medically monitored 24-hour
registered nursing care under the supervision of a medical director."1 69 South
Dakota's Second Benchmark Plan contains a similar limitation; that is,
benefits for care provided in residential treatment facilities are only available
if "treatment is provided as an inpatient at an acute level of care with 24-hour
registered nursing care under the supervision of a medical director."o 17
Oregon's Second Benchmark Plan limits coverage of services provided in a
163. BLUECROSS BLUESHIELD OF NEB., BLUEPRIDE PLUS 28 (2014),
https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/NE-BMP.zip (last visited
Mar. 14, 2019).
164. BLUE CROSS BLUE SHIELD OF N.D., BLUECARE 90 500 at 28, 36,
https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/ND-BMP.zip (last visited
Mar. 14, 2019) (excluding from coverage residential treatment services for insureds twenty-one-
years-of-age and older).
165. BLUE CROSS BLUE SHIELD OF R.I., SUBSCRIBER AGREEMENT: VANTAGEBLUE RX
$3/12/35/60/100, at 26-27 (2014), https://www.cms.gov/CCIIO/Resources/Data-
Resources/Downloads/RI-BMP.zip (last visited Mar. 14, 2019) (excluding from coverage
"extended stay/long term residential . . . programs").
166. BLUECROSS BLUESHIELD OF S.C., BUSINESS BLUE 31 (2008),
https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/2017-BMP-Summary
SC-4816.zip (last visited Mar. 14, 2019).
167. BLUECROSS BLUESHIELD OF TEX., YOUR HEALTH CARE BENEFITS PROGRAM:
SAMPLE RSH3 48 (2010), https://www.cms.gov/CCIIO/Resources/Data-
Resources/Downloads/TX-BMP.zip (last visited Mar. 14, 2019) (excluding from coverage
"[r]esidential level of treatment for Chemical Dependency in a Chemical Dependency Treatment
Center").
168. PUB. EMP. HEALTH PROGRAM, UTAH BASIC PLUS PLAN 32 (2013),
https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/2017-BMP-Summary
UT-4816.zip (last visited Mar. 14, 2019).
169. WELLMARK IOWA, COVERAGE MANUAL: COMPLETEBLUE 2000 B BlueRx Essentials
15 (2014), https://downloads.cms.gov/cciio/20170%`20Benchmark%/`20Summary_IA.zip (last
visited Mar. 14, 2019).
170. WELLMARK S.D., BLUESELECT BLUERX PREFERRED 15-16 (2013),
https://downloads.cms.gov/cciio/20170%`20Benchmark%/`20SummarySD.zip (last visited Mar.
14, 2019).
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residential facility to forty-five days.' 7 ' The Second Benchmark Plans of
Idaho and Vermont require prior authorization for services provided in a
residential treatment facility. 172
G. Some State Benchmark Plans Exclude Methadone from Coverage
Some state benchmark plans expressly cover methadone as a treatment or
service for opioid use disorder. Washington's Second Benchmark Plan, for
example, covers "[p]rescription [m]edications that are prescribed and
dispensed through a substance use disorder treatment facility (such as
methadone)."1 73 Maryland's Second Benchmark Plan covers "[m]ethadone
[m]aintenance."1 74 Minnesota's Second Benchmark Plan covers "opiate
replacement therapy including methadone and buprenorphine treatment." 75
Other state benchmark plans expressly exclude methadone from
coverage. Alabama's Second Benchmark Plan excludes "[s]ervices related to
narcotic maintenance therapy such as methadone maintenance therapy" when
care is coordinated by an Expanded Psychiatric Services (EPS) provider.1 76
Arkansas' Second Benchmark Plan expressly excludes from coverage
"[m]edications used to sustain or support an addiction or substance
dependency."' 7 7 Delaware's Second Benchmark Plan includes methadone in
its list of "What Is Not Covered." 78 Kentucky's Second Benchmark Plan
excludes "[m]ethadone treatment as maintenance, L.A.A.M. (1-Alpha-
Acetyl-Methadol), Cyclazocine, or their equivalents."1 79 Rhode Island's
Second Benchmark Plan provides that, "[t]his agreement does NOT cover
171. PACIFICSOURCE HEALTH PLANS, PREFERRED CODEDUCT VALUE 3000+35/70%
0812 TIERED VALUE Rx 10/50/75 0812, at 19-20 (2014),
https://downloads.cms.gov/cciio/20170%`20Benchmark%/`20SummaryOR.zip (last visited Mar.
14, 2019).
172. BLUE CROSS OF IDAHO, supra note 48, at 8; BLUECROSS BLUESHIELD OF VT.,
STANDARD CDHP PLAN CERTIFICATE 2 (2014), https://www.cms.gov/CCIIO/Resources/Data-
Resources/Downloads/VT-BMP.zip (last visited Mar. 14, 2019).
173. REGENCE BLUESHIELD, REGENCE DIRECT POLICY: INDIVIDUAL GROUP NUMBER:
38005001 18 (2017), https://www.assets.regence.com/policy/2017/WA/Silver3000
PreferredWashington-dv.pdf (last visited Mar. 14, 2019).
174. CAREFIRST BLUECHOICE, supra note 158, at C-8.
175. HEALTHPARTNERS, supra note 162, at 7.
176. BLUE CROSS BLUE SHIELD OF ALA., supra note 141, at 15.
177. HEALTH ADVANTAGE, GOLD: POINT OF SERVICE EVIDENCE OF COVERAGE 37
(2014), https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/Arkansas-
BMP.zip (last visited Mar. 14, 2019).
178. HIGHMARK BLUE CROSS BLUE SHIELD DEL., SMALL GROUP HEALTH PLAN: SHARED
COST EPO $2000-100 PLAN 44-45 (2014), https://www.cms.gov/CCIIO/Resources/Data-
Resources/Downloads/2017-Benchmark-SummaryDE-4 816.zip (last visited Mar. 14, 2019).
179. UNITEDHEALTHCARE OF KY., supra note 50, at 34.
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methadone clinics and treatments," and further provides that "[m]ethadone
dispensed to treat chemical dependency is NOT covered."'s Wisconsin's
Second Benchmark Plan expressly excludes from coverage "[m]ethadone
treatment as maintenance, L.A.A.M. (1 -Alpha-Acetyl-Methadol),
Cyclazocine, or their equivalents.""' Although Massachusetts' Second
Benchmark Plan does not exclude methadone from coverage, the
Massachusetts Plan does apply a prior authorization requirement to such
coverage. 182
H. Some State Benchmark Plans Exclude Mutual Support Groups from
Coverage
Some state benchmark plans exclude mutual support groups from
coverage. For example, Alaska's Second Benchmark Plan excludes from
coverage "voluntary support groups, such as Alanon or Alcoholics
Anonymous." 8 3 Connecticut's Second Benchmark Plan excludes from
coverage "[n]on-medical supportive counseling services (individual or group)
for alcohol or substance abuse (e.g., Alcoholics Anonymous)."' 84 Rhode
Island's Second Benchmark Plan is similar: "This agreement does NOT cover
the following substance abuse treatment services: [r]ecreation therapy, non-
medical self-care, or self-help training (e.g., Alcoholics Anonymous (AA),
Narcotics Anonymous (NA) meetings/services)."is8 As a practical matter,
AA, NA, and many other mutual support groups have no dues or fees
(although they may take voluntary collections during meetings), 8 6 so this
exclusion is only relevant to individuals who attend mutual support groups
that charge members to participate.
180. BLUE CROSS BLUE SHIELD OF R.I., supra note 165, at 27, 81 (emphasis removed).
181. UNITEDHEALTHCARE INS., UNITEDHEALTHCARE CHOICE PLUS 31,
https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/2017-BMP-
SummaryWI-4 816.zip (last visited Mar. 14, 2019).
182. BLUE CROSS & BLUE SHIELD OF MASS., supra note 137, at 14-15.
183. PREMERA BLUE CROSS BLUE SHIELD OF ALASKA, HERITAGE SELECT ENvOY 28
(2014), https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/2017-Benchmark-
SummaryAK.zip (last visited Mar. 14, 2019).
184. CONNECTICARE INS. Co., supra note 147, at 55.
185. BLUE CROSS BLUE SHIELD OF R.I., supra note 165, at 26 (emphasis removed).
186. Frequently Asked Questions from People New to AA, How Much Does AA
Membership Cost?, ALCOHOLICS ANONYMous, https://aa.org.au/new-to-aa/frequently-asked-
questions (last visited Mar. 14, 2019) ("There are no dues or fees for AA membership. An AA
group will usually have a collection during the meeting to cover expenses, such as rent, coffee
etc., Members are free to contribute as much or as little as they wish.").
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I. Two Benchmark Plans Establish Quantitative Treatment Limitations
Applicable Only to Mental Health and Substance Use Disorder
Benefits
The Second Benchmark Plan of Alabama limits individuals seeking
inpatient mental health and substance use disorder care to coverage of thirty
inpatient days and twenty outpatient visits per year.'8 7 Because the Alabama
plan does not appear to contain comparable limitations applicable to non-
mental health and non-substance use disorder care, these quantitative
treatment limitations may violate mental health parity law. The Second
Benchmark Plan of Mississippi contains similar quantitative treatment
limitations; that is, seven inpatient days and twenty outpatient days per
year.'8" Because the Mississippi plan does not appear to contain comparable
limitations applicable to non-mental health and non-substance use disorder
care, these limitations may likewise violate mental health parity law.
J. One Benchmark Plan Expressly Excludes Coverage for Chemical
Dependency Treatments and Services
The Second Benchmark Plan of Alaska defines "chemical dependency"
as "an illness characterized by physiological or psychological dependency, or
both, on alcohol or a state-regulated controlled substance." 89 The Alaska plan
excludes from coverage: (1) "chemical dependency services and supplies
related to the diagnosis or treatment of chemical dependency"; 190 (2)
treatments for chemical dependency provided in the emergency room other
than "medically necessary detoxification services" provided in the emergency
room;' 9' and (3) treatments for chemical dependency provided in the inpatient
hospital setting, other than "medically necessary detoxification services"
provided in the inpatient hospital setting.' 92
In addition to these general chemical dependency exclusions, the Second
Benchmark Plan of Alaska contains specific exclusions that include opioid
treatments and services. That is, the Alaska plan excludes coverage of
diagnoses and treatments for substance abuse codes 303.0 through 305.9,
187. BLUE CROSS BLUE SHIELD OF ALA., supra note 141, at 15-16.
188. BLUE CROSS & BLUE SHIELD OF MISS., PLAN DESCRIPTION NETWORK BLUE 13,
https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/2017-BMP-
SummaryMS-4816.zip (last visited Mar. 14, 2019).
189. PREMERA BLUE CROSS BLUE SHIELD OF ALASKA, supra note 183, at 53.
190. Id. at 28.
191. Id. at 12.
192. Id. at 13.
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among other codes.1 93 The DSM-IV, the edition of the DSM to which the plan
refers for purposes of definitions and other references, codes opioid
dependence as 304 and opioid abuse as 305.5.194 The result is that diagnostic
and treatment services for opioid use disorder are not covered under the
Alaska plan. In terms of its opioid use disorder coverage, the Alaska plan is
the most restrictive plan among all the state benchmark plans that the Author
has reviewed.
V. CONCLUSIONS
The extent to which a health insurance policy or plan must provide
coverage for treatments and services-and parity in such coverage-for
individuals with opioid use disorder following the December 14, 2018, United
States District Court for the Northern District of Texas opinion (District Court
Opinion) is relatively complex. First, it is important to note that the
invalidation of the entire ACA to the extent affirmed by the United States
Court of Appeals for the Fifth Circuit and/or the United States Supreme
Court-does not invalidate the original Mental Health Parity Act (MHPA),
which President Clinton signed into law in 1996, or the Paul Wellstone and
Pete Domenici Mental Health Parity and Addiction Equity Act, which
President George W. Bush signed into law in 2008. The District Court
Opinion also does not invalidate the 21st Century Cures Act, signed into law
by President Obama in 2016, or the SUPPORT Act, which President Trump
signed into law in 2018. Health plans that are governed by these four federal
laws-as well as analogous state laws must continue to comply with the
mental health parity requirements set forth in these laws notwithstanding the
District Court Opinion.
However, the District Court Opinion's invalidation of the entire ACA
to the extent affirmed includes an invalidation of the essential health
benefits provision and the related requirement for states to select a benchmark
plan to which individual health plans, small group health plans, and other
health plans in the state must provide substantially similar benefits. The
invalidation of the ACA also means that the expansion of mental health parity
law provided for in the ACAno longer applies. In summary and to the extent
the District Court Opinion is affirmed mental health parity law will revert
to MHPA as expanded by MHPAEA, the 21st Century Cures Act, the
SUPPORT Act, and more stringent state law.
193. Id. at 30, 56 (defining psychiatric services under the plan and exclusions therefrom).
194. See AM. PSYCH. Ass'N, DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL
DISORDERS (4th ed., 1990).
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To the extent the District Court Opinion is affirmed, the ACA's EHB and
benchmark selection requirements also will fall. Remember, however, that the
Second Benchmark Plans were selected by the states from preexisting health
insurance plans that were already being sold in each state independent of the
ACA. Plans like these likely will continue to be sold post-ACA. Therefore,
these benchmark plans are helpful for understanding current and typical health
plan coverage (and limitations of such coverage) of opioid use disorder
treatments and services.
The research presented in Appendix A to this Article reveals several
points and trends relating to state benchmark plan coverage of opioid use
disorder treatments and services. First, only one state-Illinois-took
advantage of the opportunity presented by the 2018 Final Regulations to
improve coverage of opioid use disorder treatments and services. To the
extent the District Court Opinion is affirmed, however, the benefits of this
opportunity will be lost for residents of Illinois. Second, many benchmark
plans do provide comprehensive substance use disorder benefits that appear
to be at parity with offered physical health care benefits. Third, some state
benchmark plans expressly acknowledge or expressly require compliance
with state and/or federal mental health parity laws. Fourth, prior authorization
is the most common substance use disorder coverage limitation set forth in
state benchmark plans. More than half of all states impose some type of prior
authorization requirement on individuals seeking some form of substance use
disorder care in at least one inpatient or outpatient context. Fifth,
approximately two-fifths of benchmark plans cover no opioid reversal agents,
although regulations implementing the ACA which soon could be
invalidated require some health plans in these states to cover at least one
opioid reversal agent. Sixth, some benchmark plans exclude or limit coverage
of residential treatment facility care. Seventh, some state benchmark plans
exclude methadone from coverage. Eighth, two states' (Alabama's and
Mississippi's) benchmark plans establish quantitative treatment limitations
applicable to inpatient and outpatient mental health and substance use disorder
care that do not appear to apply to non-mental health and non-substance use
disorder care. As such, these limitations may violate mental health parity law.
Finally, one state's (Alaska's) benchmark plan excludes coverage of all
chemical dependency care, including opioid use disorder care. In the context
of individuals with opioid use disorder, Alaska's benchmark plan is the most
limiting of all the benchmark plans reviewed by the Author.
The Author, who is trained in law and the medical humanities but not in
epidemiology or public health, hopes this research is helpful to those who
study the social determinants of health. To the extent a lack of health insurance
coverage of opioid use disorder treatments and services is associated with a
lack of access to health care and/or health itself, the coverage limitations
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identified in this Article may be worthy of review and modification by
relevant stakeholders and policymakers.
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APPENDIX A
SECOND STATE BENCHMARK PLAN
LIMITATIONS ON OPIOID AND/OR
SUBSTANCE USE DISORDER COVERAGE
StaIte Bepnehmgrk Win Mecntail Healthi Lnd~ Sutin ic t js,, DisQuiet
(1sse/r nd Coverage PBluies
Pxrodut}t (ald Lirn aioliN Tlwrco))
1. AL Blue Cross and Blue 1. Relevant Prescription Drug Category
Shield of Alabama: and Class Counts. The plan contains the
320 Plan 95  following relevant prescription drug
category and class counts: (1)
Analgesics: Opioid Analgesics, Long-
acting: 11; (2) Analgesics Opioid
Analgesics, Short-acting: 14; (3) Anti-
Addiction/Substance Abuse Treatment
Agents: Opioid Dependence Treatments:
2; (4) Anti-Addiction: Substance Abuse
Treatment Agents: Opioid Reversal
Agents: 0. (Summary at P.5).
2. Inpatient Quantitative Service
Limitation. The plan covers up to 30
days per year for mental health
disorders, detoxification, and
rehabilitation (P.15).
3. Outpatient Quantitative Treatment
Limitation. The plan covers up to 20
outpatient visits per calendar year for
mental health and substance use disorder
care. (P.16).
4. EPS Exclusions. The plan contains an
exclusion for patients who care is
coordinated by an Expanded Psychiatric
Service (EPS) for "Services related to
narcotic maintenance therapy such as
methadone maintenance therapy" and
195. See BLUE CROSS BLUE SHIELD OF ALA., supra note 141; CTRS. FOR MEDICARE &
MEDICAID SERVS., ALABAMA 2017 EHB BENCHMARK PLAN,
https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/2017-BMP-
SummaryAL-4816.zip (last visited Mar. 14, 2019).
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Premera Blue Cross
Blue Shield of Alaska:
Alaska Heritage Select
Envoy1 9 6
care provided in a residential psychiatric
facility. (P.15).
5. Non-EPS Exclusion. The plan contains
an exclusion for patients whose care is
not coordinated by an EPS for "Services
or supplies furnished by a substance
abuse facility (including a substance
abuse residential treatment facility)."
(P.16).
1. Relevant Prescription Drug Category
and Class Counts. The plan contains the
following relevant prescription drug
category and class counts: (1)
Analgesics: Opioid Analgesics, Long-
acting: 12; (2) Analgesics Opioid
Analgesics, Short-acting: 16; (3) Anti-
Addiction/Substance Abuse Treatment
Agents: Opioid Dependence Treatments:
1; (4) Anti-Addiction: Substance Abuse
Treatment Agents: Opioid Reversal
Agents: 0. (Summary at P.7).
2. Definition of Chemical Dependency.
The plan defines chemical dependency
as "an illness characterized by
physiological or psychological
dependency, or both, on alcohol or a
state-regulated controlled substance."
(P.53).
3. General Chemical Dependency
Exclusion. The plan excludes "chemical
dependency services and supplies related
to the diagnosis or treatment of chemical
dependency," "treatment of non-
dependent alcohol or drug use or abuse,"
196. See CTRS. FOR MEDICARE & MEDICAID SERVS., ALASKA 2017 EHB BENCHMARK
PLAN, https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/2017-Benchmark-
SummaryAK.zip (last visited Mar. 14, 2019); PREMERA BLUE CROSS BLUE SHIELD OF
ALASKA, supra note 183.
2. AK
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and "voluntary support groups, such as
Alanon or Alcoholics Anonymous."
(P.28).
4. Emergency Room Coverage Exclusion.
The plan's emergency room care benefit
does not cover treatment of chemical
dependency other than "medically
necessary detoxification services."
(P.12).
5. Inpatient Hospital Coverage Exclusion.
The plan's inpatient hospital care benefit
does not cover "the treatment of
chemical dependency" other than
"medically necessary detoxification
services." (P.13).
6. Opioid Dependence and Opioid Abuse
Exclusion. The plan excludes coverage
of "diagnoses and treatments for
substance abuse, 291.0 through 292.9
and 303.0 through 305.9." The DSM-JV,
which is the edition referenced in the
plan, codes opioid dependence as 304
and opioid abuse as 305.5. (P.30, 56).
3. AZ The State of Arizona: 1. Relevant Prescription Drug Category
EPO Employee Health and Class Counts. The plan contains the
Planl97  following relevant prescription drug
category and class counts: (1)
Analgesics: Opioid Analgesics, Long-
acting: 14; (2) Analgesics Opioid
Analgesics, Short-acting: 16; (3) Anti-
Addiction/Substance Abuse Treatment
Agents: Opioid Dependence Treatments:
3; (4) Anti-Addiction: Substance Abuse
197. See BENEFIT OPTIONS, EPO PLAN (2014),
https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/2017-BMP-Summary
AZ-4816.zip (last visited Mar. 14, 2019); CTRS. FOR MEDICARE & MEDICAID SERVS., ARIZONA
2017 EHB BENCHMARK PLAN, https://www.cms.gov/CCIIO/Resources/Data-
Resources/Downloads/2017-BMP-SummaryAZ-4 816.zip (last visited Mar. 14, 2019).
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Treatment Agents: Opioid Reversal
Agents: 1. (Summary at P.13).
2. Pre-Certification Required for Inpatient
Care. The plan requires pre-certification
for inpatient mental health and substance
abuse services. (P.19).
3. Exclusions. The plan excludes coverage
of the following mental health and
substance abuse services: (1) any court
ordered treatment or therapy, or any
treatment or therapy ordered as a
condition of parole, probation or custody
or visitation evaluations unless
medically appropriate and otherwise
covered under the plan; (2) treatment of
mental disorders that have been
diagnosed as organic mental disorders
associated with permanent dysfunction
of the brain; (3) treatment of chronic
conditions not subject to favorable
modification according to generally
accepted standards of medical practice;
and (4) biofeedback for reasons other
than pain management. (P.5 5).
4. AR HMO Partners, Inc.: 1. Relevant Prescription Drug Category
Small Group Gold and Class Counts. The plan contains the
1001-1198 following relevant prescription drug
category and class counts: (1)
Analgesics: Opioid Analgesics, Long-
acting: 5; (2) Analgesics Opioid
Analgesics, Short-acting: 11; (3) Anti-
Addiction/Substance Abuse Treatment
Agents: Opioid Dependence Treatments:
2; (4) Anti-Addiction: Substance Abuse
198. See CTRS. FOR MEDICARE & MEDICAID SERVS., ARKANSAS 2017 EHB BENCHMARK
PLAN, https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/Arkansas-BMP.zip
(last visited Mar. 14, 2019); HEALTH ADVANTAGE, supra note 177.
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Treatment Agents: Opioid Reversal
Agents: 0. (Summary at P.6).
2. Prior Approval. "Coverage for many
Health Interventions for the treatment of
Mental Illness and Substance Abuse are
subject to Prior Approval from the
Company." (P.17).
3. Exclusion for Abuse of Medications.
"Medications, drugs or substances used
in an abusive, destructive or injurious
manner are not covered, except when
caused by a mental or physical illness."
(P.30).
4. Exclusion for Medications Used to
Sustain or Support Addiction.
"Medications used to sustain or support
an addiction or substance dependency
are not covered." (P.3 7).
5. Exclusion for Neurofeedback. The plan
excludes neurofeedback, including for
drug addiction. (P.35).
5. CA Kaiser Foundation 1. Relevant Prescription Drug Category
Health Plan, Inc.: and Class Counts. The plan contains the
Small Group HMO1 99  following relevant prescription drug
category and class counts: (1)
Analgesics: Opioid Analgesics, Long-
acting: 3; (2) Analgesics Opioid
Analgesics, Short-acting: 7; (3) Anti-
Addiction/Substance Abuse Treatment
Agents: Opioid Dependence Treatments:
1; (4) Anti-Addiction: Substance Abuse
Treatment Agents: Opioid Reversal
Agents: 1. (Summary at P.6).
199. See CTRS. FOR MEDICARE & MEDICAID SERVS., CALIFORNIA 2017 EHB
BENCHMARK PLAN, https://www.cms.gov/CCIIO/Resources/Data-
Resources/Downloads/2017-BMPCA.zip (last visited Mar. 14, 2019); KAISER FouND.
HEALTH PLAN, supra note 133.
802 [VOL. 70: 763
OPIOID BENCHMARKS
6. CO Kaiser Foundation 1. Relevant Prescription Drug Catego
Health Plan of and Class Counts. The plan contains the
Colorado: following relevant prescription drug
State Employee Health category and class counts: (1)
Plan 2 00  Analgesics: Opioid Analgesics, Long-
acting: 3; (2) Analgesics Opioid
Analgesics, Short-acting: 7; (3) Anti-
Addiction/Substance Abuse Treatment
Agents: Opioid Dependence Treatments:
1; (4) Anti-Addiction: Substance Abuse
Treatment Agents: Opioid Reversal
Agents: 1. (Summary at P.11).
2. Referral Required for Residential
Rehabilitation and Outpatient Services.
Residential rehabilitation and outpatient
services require a referral by a Plan
physician. (P.9).
3. Chemical Dependency Services
Exclusion. The plan excludes "[chemical
dependency] Counseling for a patient
who is not responsive to therapeutic
management, as determined by a Plan
Physician." (P.9).
4. Unique Statement. "Members who are
disruptive or abusive may have their
membership terminated for cause."
(P.9).
5. Pre-Approval for Chemical Dependency
Inpatient Services and Partial
Hospitalization. "We cover inpatient
services and partial hospitalization in a
residential rehabilitation program
approved by Kaiser Permanente for the
200. See CTRS. FOR MEDICARE & MEDICAID SERVS., COLORADO 2017 EHB BENCHMARK
PLAN, https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/2017-BMP-
SummaryCO-4816.zip (last visited Mar. 14, 2019); KAISER FOUND. HEALTH PLAN OF COLO.,
EVIDENCE OF COVERAGE (2013), https://www.cms.gov/CCIIO/Resources/Data-
Resources/Downloads/2017-BMP-SummaryCO-4816.zip (last visited Mar. 14, 2019).
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POS Plan 2 0 1
treatment of alcoholism, drug abuse or
drug addiction." (P.9).
1. Relevant Prescription Drug Category
and Class Counts. The plan contains the
following relevant prescription drug
category and class counts: (1)
Analgesics: Opioid Analgesics, Long-
acting: 10; (2) Analgesics Opioid
Analgesics, Short-acting: 12; (3) Anti-
Addiction/Substance Abuse Treatment
Agents: Opioid Dependence Treatments:
2; (4) Anti-Addiction: Substance Abuse
Treatment Agents: Opioid Reversal
Agents: 1. (Summary at P.5).
2. Pre-authorization Required for
Outpatient Visits. "Pre-Authorization is
required for some outpatient treatment
for mental health and alcohol and
substance abuse services, including
office visits, subsequent to an
evaluation." (P.34). Pre-authorization is
specifically required for "outpatient
treatment of opioid dependence" (P.82),
but not other substance use disorders.
3. Supportive Counseling Exclusion. "Non-
medical supportive counseling services
(individual or group) for alcohol or
substance abuse (e.g., Alcoholics
Anonymous)." (P.55).
8. DE Highmark Blue Cross 1. Relevant Prescription Drug Category
Blue Shield Delaware, and Class Counts. The plan contains the
Inc.: following relevant prescription drug
category and class counts: (1)
Analgesics: Opioid Analgesics, Long-
201. See CTRS. FOR MEDICARE & MEDICAID SERVS., CONNECTICUT 2017 EHB
BENCHMARK PLAN, https://www.cms.gov/CCIIO/Resources/Data-
Resources/Downloads/2017-BMP-SummaryCO-4 816.zip (last visited Mar. 14, 2019);
CONNECTICARE INS. CO., supra note 147.
7. CT
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Small Group Health
Plan Shared Cost EPO
$2000/100 Plan202
acting: 11; (2) Analgesics Opioid
Analgesics, Short-acting: 12; (3) Anti-
Addiction/Substance Abuse Treatment
Agents: Opioid Dependence Treatments:
2; (4) Anti-Addiction: Substance Abuse
Treatment Agents: Opioid Reversal
Agents: 1. (Summary at P.5).
2. Behavioral Health Facility Exclusion.
The plan excludes from coverage
"[c]ertain mental health and substance
abuse services, including . . . care at
behavioral health facilities." (P.45).
3. Exclusion for Places Solely for Drug
Addiction or Alcoholism. The plan
excludes from the definition of hospital
care (and most inpatient hospital care is
covered) care delivered in "places solely
for care of drug addiction or
alcoholism." (P.73). It is not clear
whether care for drug addiction is
covered under a separate provision.
4. Methadone Exclusion. The plan
excludes methadone from coverage.
(P.45).
9. DC Group Hospitalization 1. Relevant Prescription Drug Catego
and Medical Services, and Class Counts. The plan contains the
Inc.: following relevant prescription drug
Blue Preferred PPO category and class counts: (1)
$1,000 - 100%/80%203 Analgesics: Opioid Analgesics, Long-
acting: 10; (2) Analgesics Opioid
Analgesics, Short-acting: 12; (3) Anti-
202. See CTRS. FOR MEDICARE & MEDICAID SERVS., DELAWARE 2017 EHB BENCHMARK
PLAN, https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/2017-Benchmark-
SummaryDE-4816.zip (last visited Mar. 14, 2019); HIGHMARK BLUE CROSS BLUE SHIELD
DEL., supra note 178.
203. See CTRS. FOR MEDICARE & MEDICAID SERVS., DISTRICT OF COLUMBIA 2017 EHB
BENCHMARK PLAN, https://www.cms.gov/CCIIO/Resources/Data-
Resources/Downloads/BMP-SummaryDC-4816.zip (last visited Mar. 14, 2019); GROUP
HOSPITALIZATION & MED. SERVS., supra note 142.
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Addiction/Substance Abuse Treatment
Agents: Opioid Dependence Treatments:
2; (4) Anti-Addiction: Substance Abuse
Treatment Agents: Opioid Reversal
Agents: 1. (Summary at P.5).
2. Pre-Authorization Required for Hospital
Admissions. "Hospital admissions must
be authorized or approved by the Mental
Health and Substance Abuse
Management Program." (Pgs. B-30, B-
50).
3. Outpatient Exclusions: "Outpatient
Mental Health and Substance Abuse
Coverage is not provided for: (A)
Services solely on court order or as a
condition of parole or probation unless
approved or authorized by the CareFirst
Medical Director; (B) Intellectual
disability, after diagnosis; (C)
Psychoanalysis." (P.B-62).
4. Inpatient Exclusions. "Inpatient Mental
Health and Substance Abuse Coverage
is not provided for: (A) Admissions as a
result of a court order or as a condition
of parole or probation unless approved
or authorized by the CareFirst Medical
Director; (B) Custodial Care; (C)
Admissions solely for observation or
isolation." (P.B-62).
10. FL Blue Cross and Blue 1. Relevant Prescription Drug Category
Shield of Florida: and Class Counts. The plan contains the
BlueOptions 546220 following relevant prescription drug
category and class counts: (1)
Analgesics: Opioid Analgesics, Long-
204. See BLUE CROSS BLUE SHIELD OF FLA., supra note 160; CTRS. FOR MEDICARE &
MEDICAID SERVS., FLORIDA 2017 EHB BENCHMARK PLAN,
https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/2017-BMP-
SummaryFL-4816.zip (last visited Mar. 14, 2019).
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acting: 10; (2) Analgesics Opioid
Analgesics, Short-acting: 13; (3) Anti-
Addiction/Substance Abuse Treatment
Agents: Opioid Dependence Treatments:
2; (4) Anti-Addiction: Substance Abuse
Treatment Agents: Opioid Reversal
Agents: 0. (Summary at P.5).
2. Exclusion. "Expenses for prolonged care
and treatment of Substance Dependency
in a specialized inpatient or residential
treatment facility or inpatient
confinements that are primarily intended
as a change of environment are
excluded." (P.2-15).
3. Default Exclusion. "All Inpatient
Rehabilitation Services for Substance
Dependency, drug and alcohol related
diagnoses (except as otherwise covered
in the Substance Dependency category),
Pain Management, and respiratory
ventilator management Services are
excluded."
4. Prior Authorization Required. "You or
your Physician will be required to obtain
prior coverage authorization from us for
Mental Health and Substance
Dependency Care and Treatment
Services." (Endorsement at P.2).
5. Other Exclusions. An amendment to the
plan also excludes the following:
"Services for court-ordered care or
testing, or required as a condition of
parole or probation; ... inpatient stays
that are primarily intended as a change
of environment; and inpatient
(overnight) mental health services
received in a residential treatment
facility." (Endorsement at P.1-2).
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Residential Care Facilities Outside
Hawaii. (P.46).
13. ID Blue Cross of Idaho 1. Relevant Prescription Drug Category
Health Service, Inc.: and Class Counts. The plan contains the
following relevant prescription drug
205. See CTRS. FOR MEDICARE & MEDICAID SERVS., GEORGIA 2017 EHB BENCHMARK
PLAN, https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/GA-BMP.zip (last
visited Mar. 14, 2019); HUMANA EMP. HEALTH PLAN OF GA., supra note 143.
206. See CTRS. FOR MEDICARE & MEDICAID SERVS., HAWAII 2017 EHB BENCHMARK
PLAN, https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/2017-Benchmark-
SummaryHI-4816.zip (last visited Mar. 14, 2019); HMSA BLUE CROSS BLUE SHIELD OF
HAW., GUIDE TO BENEFITS: PREFERRED PROVIDER PLAN 2010
https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/2017-Benchmark-
SummaryHI-4816.zip (last visited Mar. 14, 2019).
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1. Relevant Prescription Drug Category
and Class Counts. The plan contains the
following relevant prescription drug
category and class counts: (1)
Analgesics: Opioid Analgesics, Long-
acting: 11; (2) Analgesics Opioid
Analgesics, Short-acting: 12; (3) Anti-
Addiction/Substance Abuse Treatment
Agents: Opioid Dependence Treatments:
2; (4) Anti-Addiction: Substance Abuse
Treatment Agents: Opioid Reversal
Agents: 1. (Summary at P.4).
1. Relevant Prescription Drug Category
and Class Counts. The plan contains the
following relevant prescription drug
category and class counts: (1)
Analgesics: Opioid Analgesics, Long-
acting: 11; (2) Analgesics Opioid
Analgesics, Short-acting: 12; (3) Anti-
Addiction/Substance Abuse Treatment
Agents: Opioid Dependence Treatments:
2; (4) Anti-Addiction: Substance Abuse
Treatment Agents: Opioid Reversal
Agents: 0. (Summary at P.4).





category and class counts: (1)
Analgesics: Opioid Analgesics, Long-
acting: 9; (2) Analgesics Opioid
Analgesics, Short-acting: 13; (3) Anti-
Addiction/Substance Abuse Treatment
Agents: Opioid Dependence Treatments:
2; (4) Anti-Addiction: Substance Abuse
Treatment Agents: Opioid Reversal
Agents: 1. (Summary at P.6).
2. Prior Authorization Required for Certain
Mental Health and Substance Use
Disorder Services. Prior authorization is
required for the following mental health
and substance abuse services: outpatient
Psychotherapy services after the tenth
(10th) visit (does not include medication
management services); intensive





testing; electroconvulsive therapy (ECT)
(8).
3. Non-Emergency Pre-Admission
Notification Required for Inpatient
Admissions. The plan requires the
insured to pre-notify the plan of non-
emergency, inpatient admissions,
including those to a general hospital, an
alcohol or substance abuse treatment
facility, a psychiatric hospital, or any
other facility. (P.4).
207. See BLUE CROSS OF IDAHO, supra note 48; CTRS. FOR MEDICARE & MEDICAID
SERVS., IDAHO 2017 EHB BENCHMARK PLAN, https://www.cms.gov/CCIIO/Resources/Data-
Resources/Downloads/2017-BMPID.zip (last visited Mar. 14, 2019).
2019] 809
SOUTH CAROLINA LAW REVIEW
Blue Cross Blue
Shield of Illinois:
Blue PPO Gold 011208
1. Relevant Prescription Drug Category
and Class Counts. The plan contains the
following relevant prescription drug
category and class counts: (1)
Analgesics: Opioid Analgesics, Long-
acting: 10; (2) Analgesics Opioid
Analgesics, Short-acting: 12; (3) Anti-
Addiction/Substance Abuse Treatment
Agents: Opioid Dependence Treatments:
2; (4) Anti-Addiction: Substance Abuse
Treatment Agents: Opioid Reversal
Agents: 0. (Summary at P.5).
2. Pre-authorization Required for
"Maximum Benefits." "In order to
receive maximum benefits under this
Certificate, you must Preauthorize your
[inpatient and outpatient services] for
treatment of Mental Illness or Substance
Use Disorder by calling the Mental
Health Unit." (Pgs. 39-40).
14B. IL Illinois Access to Care 1. Relevant Prescription Drug Category
(2020) and Treatment Plan209  and Class Counts: The plan contains the
following relevant prescription drug
category and class counts: (1)
Analgesics: Opioid Analgesics, Long-
acting: 10; (2) Analgesics Opioid
Analgesics, Short-acting: 14; (3) Anti-
Addiction/Substance Abuse Treatment
Agents: Opioid Dependence Treatments:
4; (4) Anti-Addiction: Substance Abuse
Treatment Agents: Opioid Reversal
Agents: 1. (Summary at P.7).
208. See BLUECROSS BLUESHIELD OF ILL., PARTICIPATING PROVIDER OPTION,
https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/IL-BMP.zip (last visited
Mar. 14, 2019); Illinois Second Benchmark Plan, supra note 119.
209. See CTRS. FOR MEDICARE & MEDICAID SERVS., ILLINoIs EHB BENCHMARK PLAN,
https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/2020-BPM-IL.zip (last
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2. Four New Opioid-Specific Provisions.
The Illinois Access to Care and
Treatment Plan contains four new
opioid-specific provisions when
compared to the state's Second
Benchmark Plan, in effect from 2017-
2019. These provisions: (1) limit opioid
prescriptions for acute pain to no more
than 7 days ("Short-term opioid
prescriptions for acute pain will be
provided for no more than 7 days."); (2)
remove barriers to prescribing
Buprenorphine or brand equivalent
products for medication assisted
treatment of opioid use disorder through
prohibition on prior authorization,
dispensing limits, and fail first policies
for Buprenorphine or brand equivalent
products for medication assisted
treatment of opioid use disorder
("Benefits for Buprenorphine products
or brand equivalent products for
medically assisted treatment (MAT) of
opioid use disorder shall not include
prior authorization, dispensing limits,
fail first policies, or lifetime limit
requirements."); (3) provide for
coverage of at least one intranasal spray
opioid reversal agent when initial
prescriptions of opioids are dosages of
50MME or higher ("Benefits will be
provided for at least one intranasal
opioid reversal agent prescription for
initial prescriptions of opioids with
dosages of 50 MME or higher."); and (4)
provide coverage for tele-psychiatry.
(Summary at Pgs. 6; 21, 31, 32).
15. IN Anthem Insurance 1. Relevant Prescription Drug Category
Companies, Inc.: and Class Counts. The plan contains the
following relevant prescription drug
2019] 811
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Legacy PPO, Blue 6.0
Blue Access PPO
Option 14, Rx G2 10
Wellmark, Inc.:
CompleteBlue 2000211
category and class counts: (1) Opioid
Analgesics, Long-acting: 14; (2) Opioid
Analgesics, Short-acting: 16; (3) Anti-
Addiction/Substance Abuse Treatment
Agents: Opioid Dependence Treatments:
3; (4) Anti-Addiction/Substance Abuse
Treatment Agents: Opioid Reversal
Agents: 1. (Summary at P.6).
1. Relevant Prescription Drug Category
and Class Counts. The plan contains the
following relevant prescription drug
category and class counts: (1) Opioid
Analgesics, Long-acting: 5; (2) Opioid
Analgesics, Short-acting: 12; (3) Anti-
Addiction/Substance Abuse Treatment
Agents: Opioid Dependence Treatments:
2; (4) Anti-Addiction/Substance Abuse
Treatment Agents: Opioid Reversal
Agents: 0. (Summary at P.5).
2. Residential Treatment Facility
Limitation. The plan contains a
limitation for chemical dependency
services provided in a residential
treatment facility; that is, such services
are covered only when provided "on an
intensive outpatient basis, or for partial
hospitalization treatment, or for
treatment that is provided as an inpatient
at an acute level of care requiring
medically monitored 24-hour registered
nursing care under the supervision of a
medical director." (P.15).
210. See ANTHEM BLUECROSS BLUESHIELD, supra note 46; CTRS. FOR MEDICARE &
MEDICAID SERVS., INDIANA 2017 EHB BENCHMARK PLAN,
https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/IN-BMP.zip (last visited
Mar. 14, 2019).
211. See CTRS. FOR MEDICARE & MEDICAID SERVS., IOWA 2017 EHB BENCHMARK
PLAN, https://downloads.cms.gov/cciio/2017%`20Benchmark%/`20SummaryIA.zip (last visited
Mar. 14, 2019); WELLMARK IOWA, supra note 169.
16. IA
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Blue Cross and Blue
Shield of Kansas, Inc.:
Comprehensive Major
Medical - Blue





212. See BLUE CROSS BLUE SHIELD OF KAN., supra note 136; CTRS. FOR MEDICARE &
MEDICAID SERVS., KANSAS 2017 EHB BENCHMARK PLAN,
https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/2017-BMP-
SummaryKS-4816.zip (last visited Mar. 14, 2019).
213. See CTRS. FOR MEDICARE & MEDICAID SERVS., KENTUCKY 2017 EHB
BENCHMARK PLAN, https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/KY-
BMP.zip (last visited Mar. 14, 2019); UNITEDHEALTHCARE OF KY., supra note 50.
1. Relevant Prescription Drug Category
and Class Counts. The plan contains the
following relevant prescription drug
category and class counts: (1) Opioid
Analgesics, Long-acting: 10; (2) Opioid
Analgesics, Short-acting: 12; (3) Anti-
Addiction/Substance Abuse Treatment
Agents: Opioid Dependence Treatments:
2; (4) Anti-Addiction/Substance Abuse
Treatment Agents: Opioid Reversal
Agents: 1. (Summary at P.8).
1. Relevant Prescription Drug Category
and Class Counts. The plan contains the
following relevant prescription drug
category and class counts: (1) Opioid
Analgesics, Long-acting: 11; (2) Opioid
Analgesics, Short-acting: 12; (3) Anti-
Addiction/Substance Abuse Treatment
Agents: Opioid Dependence Treatments:
2; (4) Anti-Addiction/Substance Abuse
Treatment Agents: Opioid Reversal
Agents: 1. (Summary at P.5).
2. Exclusion for Certain Substance Use
Disorder Services. The plan excludes the
following substance use disorder
services: (1) Services performed in
connection with conditions not classified
in the current edition of the Diagnostic
and Statistical Manual of the American
Psychiatric Association; (2) Methadone




SOUTH CAROLINA LAW REVIEW
or their equivalents; (3) Educational/
behavioral services that are focused on
primarily building skills and capabilities
in communication, social interaction and
learning; (4) Services or supplies for the
diagnosis or treatment of alcoholism or
substance use disorders that, in the
reasonable judgment of the Mental
Health/Substance Use Disorder
Designee, are any of the following: (a)
Not consistent with generally accepted
standards of medical practice for the
treatment of such conditions; (b) Not
consistent with services backed by
credible research soundly demonstrating
that the services or supplies will have a
measurable and beneficial health
outcome, and therefore considered
experimental; (c) Not consistent with the
Mental Health/Substance Use Disorder
Designee's level of care guidelines or
best practices as modified from time to
time; and (d) Not clinically appropriate
for the patient's substance use disorder
or condition based on generally accepted
standards of medical practice and
benchmarks."
3. Requirement of a Mental
Health/Substance Use Disorder
Designee. The plan requires an
organization or individual called a
Mental Health/Substance Use Disorder
Designee that is designated by the plan
to provide or arrange for mental health
and substance use disorder services (and
to determine coverage) under the policy.
(P.15).
19. LA Louisiana Health 1. Relevant Prescription Drug Category
Service & Indemnity and Class Counts. The plan contains the
Company: following relevant prescription drug
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category and class counts: (1) Opioid
Analgesics, Long-acting: 10; (2) Opioid
Analgesics, Short-acting: 16; (3) Anti-
Addiction/Substance Abuse Treatment
Agents: Opioid Dependence Treatments:
2; (4) Anti-Addiction/Substance Abuse
Treatment Agents: Opioid Reversal
Agents: 0. (Summary at P.5).
2. Pre-Authorization Required for Inpatient
Treatment of Substance Use Disorder.
"Inpatient treatment for substance abuse
must be Authorized as provided in the
Care Management Article of this Benefit
Plan, when coverage for alcohol and/or
drug abuse is provided." (P.33).
1. Relevant Prescription Drug Category
and Class Counts. The plan contains the
following relevant prescription drug
category and class counts: (1) Opioid
Analgesics, Long-acting: 14; (2) Opioid
Analgesics, Short-acting: 16; (3) Anti-
Addiction/Substance Abuse Treatment
Agents: Opioid Dependence Treatments:
3; (4) Anti-Addiction/Substance Abuse
Treatment Agents: Opioid Reversal
Agents: 1. (Summary at 5).
2. Prior Authorization Required for
Inpatient Substance Abuse Treatment.
"Authorization for Inpatient Mental
Health and Substance Abuse services
214. See BLUECROSS BLUESHIELD OF LA., supra note 49; CTRS. FOR MEDICARE &
MEDICAID SERVS., LOUISIANA 2017 EHB BENCHMARK PLAN,
https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/2017-BMP-
SummaryLA-4816.zip (last visited Mar. 14, 2019).
215. See ANTHEM BLUECROSS BLUESHIELD, supra note 47; CTRS. FOR MEDICARE &
MEDICAID SERVS., MAINE 2017 EHB BENCHMARK PLAN,
https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/2017-BMP-
SummaryME.zip (last visited Mar. 14, 2019).
20. ME
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must be obtained through the behavioral
health care manager." (P.14).
1. Relevant Prescription Drug Category
and Class Counts. The plan contains the
following relevant prescription drug
category and class counts: (1) Opioid
Analgesics, Long-acting: 10; (2) Opioid
Analgesics, Short-acting: 2; (3) Anti-
Addiction/Substance Abuse Treatment
Agents: Opioid Dependence Treatments:
2; (4) Anti-Addiction/Substance Abuse
Treatment Agents: Opioid Reversal
Agents: 1. (Summary at 6).
2. Prior Authorization Required for
Coverage of Inpatient Hospital
Admissions for Mental Health and
Substance Use Disorder Services.
"Hospital admissions must be authorized
or approved by the Mental Health and
Substance Abuse Management Program.
Prior authorization will be obtained by
contracting providers." (P.B-30).
22. MA Blue Cross and Blue 1. Relevant Prescription Drug Catego
Shield of and Class Counts. The plan contains the
Massachusetts HMO following relevant prescription drug
Blue, Inc.: category and class counts: (1) Opioid
HMO Blue New Analgesics, Long-acting: 14; (2) Opioid
England Deductible Analgesics, Short-acting: 16; (3) Anti-
$2000217 AddictionSub stance Abuse Treatment
$2,00021 _Agents: Opioid Dependence Treatments:
216. See CAREFIRST BLUECHOICE, supra note 158; CTRS. FOR MEDICARE & MEDICAID
SERVS., MARYLAND 2017 EHB BENCHMARK PLAN,
https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/MD-BMP.zip (last visited
Mar. 14, 2019).
217. See BLUE CROSS BLUE SHIELD OF MASS., supra note 137; CTRS. FOR MEDICARE &
MEDICAID SERVS., MASSACHUSETTS 2017 EHB BENCHMARK PLAN,
https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/2017-BMP-
SummaryMA_4816.zip (last visited Mar. 14, 2019).
21. MD
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3; (4) Anti-Addiction/Substance Abuse
Treatment Agents: Opioid Reversal
Agents: 1. (Summary at 5).
2. Prior Authorization Required for
Coverage of Methadone. (P.15).
3. Prior Authorization Required for
Inpatient Mental Health Services. "To
receive coverage for inpatient services
for a mental condition, you and your
mental health provider must receive
approval from Blue Cross Blue Shield
HMO Blue as outlined in this Subscriber
Certificate before you enter a general or
mental hospital or substance abuse
treatment facility for inpatient care."
(P.45).
4. Exclusion for Wilderness and Similar
Therapies. The plan excludes from
covered mental health and substance
abuse services that "are performed in
educational, vocational, or recreational
settings; and 'outward bound-type,'
'wilderness,' 'camp,' or 'ranch'
programs." (P.45).
23. MI PriorityHealth: 1. Relevant Prescription Drug Category
PriorityHMO 218  and Class Counts. The plan contains the
following relevant prescription drug
category and class counts: (1) Opioid
Analgesics, Long-acting: 12; (2) Opioid
Analgesics, Short-acting: 13; (3) Anti-
Addiction/Substance Abuse Treatment
Agents: Opioid Dependence Treatments:
3; (4) Anti-Addiction/Substance Abuse
Treatment Agents: Opioid Reversal
Agents: 0. (Summary at P.4).
218. See CTRS. FOR MEDICARE & MEDICAID SERVS., MICHIGAN 2017 EHB BENCHMARK
PLAN, https://downloads.cms.gov/files/CCIIO/2017_benchmarksummarymi_033117.zip
(last visited Mar. 14, 2019); PRIORITYHEALTH, supra note 161.
2019] 817





2. Prior Approval Required for Inpatient
Substance Abuse Services. "Inpatient
substance abuse services (including
partial hospitalization) require Prior
Approval from our Behavioral Health
Department, except in a Medical
Emergency." (P.27).
3. Other Exclusions. "Care provided in a
home, residential or institutional facility,
or other facility on a temporary or
permanent basis is not Covered,
including the costs of living and being
cared for in . .. transitional living
centers, non-licensed programs, or
therapeutic boarding schools ... [and]
costs for care that is . . . custodial,
designed to keep you from continuing
unhealthy activities or typically provided
by community mental health services
programs." (P.26).
1. Relevant Prescription Drug Category
and Class Counts. The plan contains the
following relevant prescription drug
category and class counts: (1) Opioid
Analgesics, Long-acting: 4; (2) Opioid
Analgesics, Short-acting: 7; (3) Anti-
Addiction/Substance Abuse Treatment
Agents: Opioid Dependence Treatments:
1; (4) Anti-Addiction/Substance Abuse
Treatment Agents: Opioid Reversal
Agents: 0. (Summary at P.4).
2. Exclusion for Professional Services
Associated with Substance Abuse
Intervention. The plan excludes
professional services associated with
24. MN
219. See CTRS. FOR MEDICARE & MEDICAID SERVS., MINNESOTA 2017 EHB
BENCHMARK PLAN, https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/
2017-BMP-SummaryMN.zip (last visited Mar. 14, 2019); HEALTHPARTNERS, supra note 162.
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substance abuse interventions. The plan
defines a substance abuse intervention as
a gathering of family and/or friends to
encourage a person covered under this
contract to seek substance abuse
treatment. (GMC at P.14).
3. Exclusion for Halfway Houses and
Similar Facilities. The plan excludes
coverage of care provided in halfway
houses, extended care facilities, and
residential treatment facilities. (BC at
P. 8).
1. Relevant Prescription Drug Category
and Class Counts. The plan contains the
following relevant prescription drug
category and class counts: (1) Opioid
Analgesics, Long-acting: 8; (2) Opioid
Analgesics, Short-acting: 13; (3) Anti-
Addiction/Substance Abuse Treatment
Agents: Opioid Dependence Treatments:
2; (4) Anti-Addiction/Substance Abuse
Treatment Agents: Opioid Reversal
Agents: 0. (Summary at P.5).
2. Prior Authorization Required for
Substance Abuse Benefits. "No Benefits
will be provided unless Provider
receives Prior Authorization from
Company." (P.53).
3. Exclusion for Certain Illnesses and
Injuries. "Benefits will not be provided
for the following: illness or injury which
is caused by the Member's use or
possession of any drug or other
220. See BLUE CROSS & BLUE SHIELD OF MISS., supra note 188; CTRS. FOR MEDICARE
& MEDICAID SERVS., MISSISSIPPI 2017 EHB BENCHMARK PLAN,
https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/2017-BMP-
SummaryMS-4816.zip (last visited Mar. 14, 2019).
25. MS
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controlled substance which Member
does not lawfully possess." (P.66).
4. Quantitative Treatment Limitation for
Inpatient Drug Abuse Services. The plan
establishes a quantitative treatment
limitation for inpatient drug abuse
services of seven (7) days per year.
(P. 13).
5. Quantitative Treatment Limitation for
Outpatient Drug Abuse Services. The
plan establishes a quantitative treatment
limitation for outpatient drug abuse
services of twenty (20) days per year.
(P. 13).
6. Quantitative Financial Requirement for
Drug Abuse Services. "Coinsurance for
Covered Services incurred for the
treatment of alcohol abuse, drug abuse
and
Temporomandibular/Craniomandibular
Joint Disorder cannot be used toward
satisfying the Medical Out-of-pocket of
this Benefit Plan. Once the Medical Out-
of-pocket amount has been satisfied,
Company will not pay 100% of the
Allowable Charges for services incurred
for treatment and care of alcohol abuse,
drug abuse and Temporomandibular/
Craniomandibular Joint Disorder."
(P.36).
26. MO Healthy Alliance Life 1. Relevant Prescription Drug Category
Co. (Anthem BCBS): and Class Counts. The plan contains the
PPO On Exchange2 2 1  following relevant prescription drug
category and class counts: (1) Opioid
221. See ANTHEM BLUECROSS BLUESHIELD, supra note 124; CTRS. FOR MEDICARE &
MEDICAID SERVS., MISSOURI 2017 EHB BENCHMARK PLAN,
https://downloads.cms.gov/cciio/20170%`20Benchmark%/`20SummaryMO revised%20508.zip
(last visited Mar. 14, 2019).
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Analgesics, Long-acting: 11; (2) Opioid
Analgesics, Short-acting: 12; (3) Anti-
Addiction/Substance Abuse Treatment
Agents: Opioid Dependence Treatments:
2; (4) Anti-Addiction/Substance Abuse
Treatment Agents: Opioid Reversal
Agents: 1. (Summary at P.5).
27. MT Blue Cross and Blue 1. Relevant Prescription Drug Category
Shield of Montana: and Class Counts. The plan contains the
Blue Preferred Gold following relevant prescription drug
PPO 007222 category and class counts: (1) Opioid
Analgesics, Long-acting: 10; (2) Opioid
Analgesics, Short-acting: 12; (3) Anti-
Addiction/Substance Abuse Treatment
Agents: Opioid Dependence Treatments:
2; (4) Anti-Addiction/Substance Abuse
Treatment Agents: Opioid Reversal
Agents: 1. (Summary at P.6).
28. NE Blue Cross and Blue 1. Relevant Prescription Drug Catego
Shield of Nebraska: and Class Counts. The plan contains the
SG BCBSNE 2 Tier following relevant prescription drug
(Blue Pride Plus), category and class counts: (1) Opioid
Blue Pride Plus Analgesics, Long-acting: 10; (2) Opioid
Option 102 Gold 2 2 3  Analgesics, Short-acting: 12; (3) Anti-
Addiction/Substance Abuse Treatment
Agents: Opioid Dependence Treatments:
2; (4) Anti-Addiction/Substance Abuse
Treatment Agents: Opioid Reversal
Agents: 1. (Summary at P.5).
222. See BLUECROSS BLUESHIELD OF MONT., supra note 140; CTRS. FOR MEDICARE &
MEDICAID SERVS., MONTANA 2017 EHB BENCHMARK PLAN,
https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/2017-BMP_MT.zip (last
visited Mar. 14, 2019).
223. See BLUE CROSS BLUE SHIELD OF NEB., supra note 163; CTRS. FOR MEDICARE &









2. Pre-Certification Required for Inpatient
Substance Use Disorder Services. The
plan states that Inpatient Services for
Mental Illness or Substance Dependence
and Abuse must be Certified by
BCBSNE. (P.17).
3. Exclusion for Residential Treatment
Programs. The plan excludes mental
health and substance use disorder care
provided in a residential treatment
program. (P.28).
4. Exclusion from the Definition of
Outpatient Program. The plan excludes
from the definition of Outpatient
Program "Residential Treatment
Programs or day rehabilitation programs
for Mental Illness, or Residential
Treatment Programs, halfway house or
methadone maintenance programs for
Substance Dependence and Abuse."
(P.5 8).
1. Relevant Prescription Drug Category
and Class Counts. The plan contains the
following relevant prescription drug
category and class counts: (1) Opioid
Analgesics, Long-acting: 11; (2) Opioid
Analgesics, Short-acting: 12; (3) Anti-
Addiction/Substance Abuse Treatment
Agents: Opioid Dependence Treatments:
2; (4) Anti-Addiction/Substance Abuse
Treatment Agents: Opioid Reversal
Agents: 1. (Summary at P.5).
2. Prior Authorization Required. "All
Inpatient and non-routine Outpatient
224. See CTRS. FOR MEDICARE & MEDICAID SERVS., supra note 105, HEALTH PLAN OF
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non-Emergency Mental Health, Severe
Mental Illness, and Substance Abuse
Services, including Intensive outpatient
program treatment, Outpatient electro-
convulsive treatment, Psychological
testing and Extended outpatient
treatment visits beyond 45 - 50 minutes
in duration, with or without medication
management" require prior authorization
and review. (Pgs. 12, 20).
30. NH Anthem: 1. Relevant Prescription Drug Category
Matthew Thornton and Class Counts. The plan contains the
Blue HM0 2 25  following relevant prescription drug
category and class counts: (1) Opioid
Analgesics, Long-acting: 11; (2) Opioid
Analgesics, Short-acting: 14; (3) Anti-
Addiction/Substance Abuse Treatment
Agents: Opioid Dependence Treatments:
2; (4) Anti-Addiction/Substance Abuse
Treatment Agents: Opioid Reversal
Agents: 1. (Summary at P.5).
31. NJ Horizon Healthcare 1. Relevant Prescription Drug Category
Services, Inc.: and Class Counts. The plan contains the
Advantage EPO following relevant prescription drug
Silver 100/50226 category and class counts: (1) Opioid
Analgesics, Long-acting: 10; (2) Opioid
Analgesics, Short-acting: 12; (3) Anti-
Addiction/Substance Abuse Treatment
Agents: Opioid Dependence Treatments:
2; (4) Anti-Addiction/Substance Abuse
225. See ANTHEM BLUECROSS BLUESHIELD, GUIDED ACCESS CERTIFICATE OF
COVERAGE (2014), https://downloads.cms.gov/cciio/20170%`20Benchmark%/`20Summary
NH.zip (last visited Mar. 14, 2019); CTRS. FOR MEDICARE & MEDICAID SERVS., NEW
HAMPSHIRE 2017 EHB BENCHMARK PLAN, https://downloads.cms.gov/
cciio/2017%20Benchmark%20SummaryNH.zip (last visited Mar. 14, 2019).
226. See CTRS. FOR MEDICARE & MEDICAID SERVS., NEW JERSEY 2017 EHB
BENCHMARK PLAN, https://downloads.cms.gov/cciio/bmp-summary-nj.zip (last visited Mar.
14, 2019); HORIZON BLUE CROSS BLUE SHIELD OF N.J., supra note 138.
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Treatment Agents: Opioid Reversal
Agents: 1 (Summary at P.5).
1. Relevant Prescription Drug Category
and Class Counts. The plan contains the
following relevant prescription drug
category and class counts: (1) Opioid
Analgesics, Long-acting: 9; (2) Opioid
Analgesics, Short acting: 10; (3) Anti-
Addiction/Substance Abuse Treatment
Agents: Opioid Dependence Treatments:
2; (4) Anti-Addiction/Substance Abuse
Treatment Agents Opioid Reversal
Agents: 0 (Summary at P.5).
2. Exclusions Applicable to Substance Use
Disorders. The plan contains exclusions
for treatments in a halfway house,
codependency, bereavement,
pastoral/spiritual and sexual counseling,
court-ordered treatment, or treatment
that is a condition of parole or probation
or in lieu of sentencing, and any
treatment for Alcoholism and/or
Substance Abuse services after the
maximum episodes of treatment allowed
under this Agreement have been
completed is not Covered. (P.78).
33. NY Oxford Health 1. Relevant Prescription Drug Category
Insurance, Inc.: and Class Counts. The plan contains the
Oxford EPO2 2 8 following relevant prescription drug
227. See CTRS. FOR MEDICARE & MEDICAID SERVS., NEW MEXICO 2017 EHB
BENCHMARK PLAN, https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/
2017-BMP-SummaryNM-4816.zip (last visited Mar. 14, 2019); PRESBYTERIAN HEALTH
PLAN, SUBSCRIBER AGREEMENT AND GUIDE TO YOUR MANAGED CARE PLAN (2013),
https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/2017-BMP-
SummaryNM-4816.zip (last visited Mar. 14, 2019).
228. See CTRS. FOR MEDICARE & MEDICAID SERVS., NEW YORK 2017 EHB BENCHMARK
PLAN, https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/NY-BMP.zip (last
visited Mar. 14, 2019); OXFORD HEALTH INS., CERTIFICATE OF COVERAGE (2014),
32. NM
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category and class counts: (1) Opioid
Analgesics, Long-acting: 12; (2) Opioid
Analgesics, Short-acting: 15; (3) Anti-
Addiction/Substance Abuse Treatment
Agents: Opioid Dependence Treatments:
2; (4) Anti-Addiction/Substance Abuse
Treatment Agents: Opioid Reversal
Agents: 0. (Summary at P.5).
2. Outpatient Treatment Limitations. The
plan covers outpatient substance use
services relating to the diagnosis and
treatment of alcoholism and/or substance
use and/or dependency; however, that
coverage is limited to facilities in New
York State, certified by the Office of
Alcoholism and Substance Abuse
Services (OASAS) or licensed by
OASAS as outpatient clinics or
medically supervised ambulatory
substance abuse programs or by
Physicians who have been granted a
waiver pursuant to the Drug Addiction
and Treatment Act of 2000 to prescribe
Schedule III, IV and V narcotic
medications for the treatment of opioid
addiction during the acute detoxification
stage of treatment or during stages of
rehabilitation; and, in other states, to
those accredited by the Joint
Commission as alcoholism or chemical
dependence treatment programs.
Coverage is also available in a
professional office setting for outpatient
substance use services relating to the
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and/or substance use and/or dependency.
(P.46).
3. Inpatient Treatment Limitations. The
plan covers inpatient substance use
services relating to the diagnosis and
treatment of alcoholism and/or substance
use and/or dependency. This includes
Coverage for detoxification and/or
rehabilitation services as a consequence
of chemical use and/or substance use.
Inpatient substance use services are
limited to Facilities in New York which
are certified by the Office of Alcoholism
and Substance Abuse Services
(OASAS), and in other states, to those
which are accredited by the Joint
Commission as alcoholism, substance
abuse or chemical dependence treatment
programs. (P.46).
4. Quantitative Treatment Limitations for
Family Counseling. The plan covers up
to 20 outpatient visits for family
counseling. A family member will be
deemed to be covered, for the purposes
of this provision, so long as that family
member: (i) identifies himself or herself
as a family member of a person suffering
from substance use and/or dependency,
and (ii) is covered under the same family
Certificate that covers the person
receiving, or in need of, treatment for
substance use, and/or dependence. Our
payment for a family member therapy
session will be the same amount,
regardless of the number of family
members who attend the family therapy
session.
34. NC Blue Cross and Blue 1. Quantitative Treatment Limitations
Shield of North Applicable to Prescription Opioids and
Carolina: Treatments for Opioid Use Disorder.
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Blue Options PPO" The plan establishes the following
quantitative treatment limitations: (1)
Analgesics: Opioid Analgesics, Long-
acting: 11; (2) Analgesics: Opioid
Analgesics, Short-acting: 14; (3) Anti-
Addiction/Substance Abuse Treatment
Agents: Opioid Dependence Treatments:
2; (4) Anti-Addiction/Substance Abuse
Treatment Agents: Opioid Reversal
Agents: 0. (Summary at P.6).
2. Prior Review Required. "For mental
health and substance abuse services,
BCBSNC delegates the administration
of these benefits to Magellan Behavioral
Health, which is not associated with
BCBSNC. You must contact Magellan
Behavioral Health directly and request
prior review for inpatient and certain
outpatient services, except in
emergencies." (P.6).
3. Substance Use Disorder Exclusions. The
plan excludes counseling with relatives
about a patient and inpatient
confinements that are primarily intended
as a change of environment. (P.3 3).
229. See BLUECROSS BLUESHIELD OF N.C., BENEFIT BOOKLET FOR EMPLOYEES OF
BLUE OPTIONS SMALL GROUP FOR BLUE OPTIONS (2012),
https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/2017-BMPNC.zip (last
visited Mar. 14, 2019); CTRS. FOR MEDICARE & MEDICAID SERVS., NORTH CAROLINA 2017
EHB BENCHMARK PLAN, https://www.cms.gov/CCIIO/Resources/Data-
Resources/Downloads/2017-BMP NC.zip (last visited Mar. 14, 2019).
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35. ND Blue Cross Blue 1. Relevant Prescription Drug Category
Shield of North and Class Counts. The plan contains the
Dakota: following relevant prescription drug
BlueCare Gold 90 category and class counts: (1)
500230 Analgesics: Opioid Analgesics, Long-
acting: 10; (2) Analgesics: Opioid
Analgesics, Short-acting: 12; (3) Anti-
Addiction/Substance Abuse Treatment
Agents: Opioid Dependence Treatments:
2; (4) Anti-Addiction/Substance Abuse
Treatment Agents: Opioid Reversal
Agents: 1 (Summary at P.8).
2. Preauthorization Required for Inpatient,
Intensive Outpatient, and Residential
Treatment for Substance Use Disorder
Services. (Pgs. 14, 34).




Program (IOP), Partial Hospitalization
program (PHP) setting, or Residential
Treatment detoxification." (28). "No
benefits are available for the Residential
Treatment of substance abuse for
Members age 21 and older." (P.28).
230. See BLUE CROSS BLUE SHIELD OF N.D., supra note 164; CTRS. FOR MEDICARE &
MEDICAID SERVS., NORTH DAKOTA 2017 EHB BENCHMARK PLAN,
https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/ND-BMP.zip (last visited
Mar. 14, 2019).
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36. OH Community Insurance 1. Relevant Prescription Drug Catego
Company (Anthem and Class Counts. The plan contains the
BCBS): following relevant prescription drug
Blue Access (PPO) - category and class counts: (1)
Standard Opt D55 2 3 1  Analgesics: Opioid Analgesics, Long-
acting: 14; (2) Analgesics: Opioid
Analgesics, Short-acting: 16; (3) Anti-
Addiction/Substance Abuse Treatment
Agents: Opioid Dependence Treatments:
3; (4) Anti-Addiction/Substance Abuse
Treatment Agents: Opioid Reversal
Agents: 1. (Summary at P.14).
2. Exclusions. The plan excludes: *
Custodial Care, convalescent care or rest
cures; * Domiciliary care provided in a
residential institution, treatment center,
supervised living or halfway house, or
school because a Member's own home
arrangements are not available or are
unsuitable, and consisting chiefly of
room and board, even if therapy is
included; * Care provided or billed by a
hotel, health resort, convalescent home,
rest home, nursing home or other
extended care facility home for the aged,
infirmary, school infirmary, institution
providing education in special
environments, supervised living or
halfway house, or any similar facility or
institution; * Services or care provided or
billed by a school, Custodial Care center
for the developmentally disabled,
halfway house, or outward bound
programs, even if psychotherapy is
231. See ANTHEM BLUECROSS BLUESHIELD, HEALTH CERTIFICATE OF COVERAGE
(2015), https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/2017-BMP-
SummaryOH-4816.zip (last visited Mar. 14, 2019); CTRS. FOR MEDICARE & MEDICAID
SERVS., OHIO 2017 EHB BENCHMARK PLAN, https://www.cms.gov/CCIIO/Resources/Data-
Resources/Downloads/2017-BMP-SummaryOH-4 816.zip (last visited Mar. 14, 2019).
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included; and * Wilderness camps. (P.
M-52).
1. Relevant Prescription Drug Category
and Class Counts. The plan contains the
following relevant prescription drug
category and class counts: (1)
Analgesics: Opioid Analgesics, Long-
acting: 10; (2) Analgesics: Opioid
Analgesics, Short-acting: 12; (3) Anti-
Addiction/Substance Abuse Treatment
Agents: Opioid Dependence Treatments:
2; (4) Anti-Addiction/Substance Abuse
Treatment Agents: Opioid Reversal
Agents: 0. (Summary at P.6).
2. Pre-authorization Required for Certain
Substance Use Disorder Services. All
Inpatient services related to treatment of
drug addiction and substance abuse or
alcoholism must be Preauthorized by the
Plan. Preauthorization is also required
for the following Outpatient Psychiatric
232. See BLUECROSS BLUESHIELD OF OKLA., CERTIFICATE OF BENEFITS,
https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/2017-Benchmark-
SummaryOK-4816.zip (last visited Mar. 31, 2019); CTRS. FOR MEDICARE & MEDICAID
SERVS., OKLAHOMA 2017 EHB BENCHMARK PLAN,
https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/2017-Benchmark-
SummaryOK-4816.zip (last visited Mar. 31, 2019).
37. OK








Care Services: Psychological testing;
Neuropsychological testing;
Electroconvulsive therapy; and Intensive
Outpatient Treatment. (Pgs. 5-6).
1. Relevant Prescription Drug Category
and Class Counts. The plan contains the
following relevant prescription drug
category and class counts: (1)
Analgesics: Opioid Analgesics, Long-
acting: 11; (2) Analgesics: Opioid
Analgesics, Short-acting: 13; (3) Anti-
Addiction/Substance Abuse Treatment
Agents: Opioid Dependence Treatments:
2; (4) Anti-Addiction/Substance Abuse
Treatment Agents Opioid Reversal
Agents: 1. (Summary at P.4).
2. Prior Authorization for Inpatient Mental
Health Services Required. (P.29).
3. Limitations and Exclusions Applicable
to Chemical Dependency Services. (1)
"Benefits for long-term residential
mental health programs exceeding 45
days of treatment per calendar year will
not be authorized"; (2) A second opinion
may be required for a medical necessity
determination. Pacific Source will notify
38. OR
233. See CTRS. FOR MEDICARE & MEDICAID SERVS., OREGON 2017 EHB BENCHMARK
PLAN, https://downloads.cms.gov/cciio/20170%`20Benchmark%/`20SummaryOR.zip (last
visited Mar. 14, 2019); PACIFICSOURCE HEALTH PLANS, supra note 171.
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the patient when this requirement is
applicable; (3) Pacific Source must be
notified of an emergency admission
within two business days; (4) treatment
of substance abuse and related disorders
is subject to placement criteria
established by the American Society of
Addiction Medicine. (Pgs. 19-20).
4. Exclusions Applicable to Mental Health
Services. (1) Court-ordered screening
interviews or drug or alcohol treatment
programs; (2) Marital/partner
counseling; and (3) Support groups
(P.28).
1. Relevant Prescription Drug Category
and Class Counts. The plan contains the
following relevant prescription drug
category and class counts: (1)
Analgesics: Opioid Analgesics, Long-
acting: 11; (2) Analgesics: Opioid
Analgesics, Short-acting: 12; (3) Anti-
Addiction/Substance Abuse Treatment
Agents: Opioid Dependence Treatments:
2; (4) Anti-Addiction/Substance Abuse
Treatment Agents: Opioid Reversal
Agents: 0. (Summary at P.6).
2. Pre-Approval Required for IOP and PHP
Services. "All Intensive Outpatient
Program and Partial Hospitalization
services must be approved by the Health
Benefit Plan." (P.3 3).
3. Exclusions Applicable to Mental Health
Care. "For any Mental Health Care,
234. See CTRS. FOR MEDICARE & MEDICAID SERVS., PENNSYLVANIA 2017 EHB
BENCHMARK PLAN, https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/PA-













Serious Mental Illness Health Care, or
Alcohol or Drug Abuse And
Dependency modalities that have not
been incorporated into the commonly
accepted therapeutic repertoire as
determined by broad-based professional
consensus, such as: Alternative
Therapies/Complementary Medicine and
obesity control therapy except as
otherwise provided in this Program;
Non-medical services, such as
vocational rehabilitation or employment
counseling, for the treatment of Alcohol
or Drug Abuse and Dependency in an
acute care Hospital." (P.70).
1. Relevant Prescription Drug Category
and Class Counts. The plan contains the
following relevant prescription drug
category and class counts: (1)
Analgesics Opioid Analgesics, Long-
acting: 10; (2) Analgesics: Opioid
Analgesics, Short-acting: 15; (3) Anti-
Addiction/Substance Abuse Treatment
Agents: Opioid Dependence Treatments:
2; (4) Anti-Addiction/Substance Abuse
Treatment Agents: Opioid Reversal
Agents: 1. (Summary at P.4).
2. Exclusion for Methadone Clinics and
Methadone Treatments. "This agreement
does NOT cover methadone clinics and
treatments." (P.26). "Methadone
dispensed to treat chemical dependency
is NOT covered." (P.81).
235. See BLUE CROSS BLUE SHIELD OF R.I., supra note 165; CTRS. FOR MEDICARE &





SOUTH CAROLINA LAW REVIEW
3. Pharmacy Limitation. "We may limit
your selection of a pharmacy to one (1)
network pharmacy. Those members
subject to this restriction include, but are
not limited to, members that have a
history of: being prescribed prescription
drugs by multiple physicians; having
prescriptions drugs filled at multiple
pharmacies; being prescribed certain
long acting opioids and other controlled
substances, either in combination or
separately, that suggests a need for
monitoring due to: quantities dispensed;
daily dosage range; or the duration of
therapy exceeds reasonable and
established thresholds." (Pgs. 57-58).
4. Substance Use Disorder Exclusions.
"This agreement does NOT cover the
following substance abuse treatment
services: Recreation therapy, non-
medical self-care, or self-help training
(e.g., Alcoholics Anonymous (AA),
Narcotics Anonymous (NA)
meetings/services); Telephone
consultations (See Section 4.16);
Therapeutic recreation programs,
extended stay/long term residential or
wilderness programs; services provided
in any covered program that are
reviewed by us and we decide are
recreation therapy programs, wilderness
programs, educational programs,
complimentary programs, or non-clinical
services (examples of services that are
not covered include, but is not limited to,
Tai Chi, yoga, personal training,
meditation, and internet based
support/education); Computer
based/internet /social media services
and/or programs. This agreement does
NOT cover substance abuse treatment
834 [VOL. 70: 763
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when: the provider does NOT meet our
eligibility and/or credentialing
requirements; the program is not
approved by us for benefit coverage; or
treatment is rendered at facilities that are
not approved and/or licensed by the state
in which the facility is located. This
agreement does NOT cover methadone
clinics and treatments." (Pgs. 26-27).
1. Relevant Prescription Drug Category
and Class Counts. The plan contains the
following relevant prescription drug
category and class counts: (1)
Analgesics: Opioid Analgesics, Long-
acting: 14; (2) Analgesics Opioid
Analgesics, Short-acting: 16; (3) Anti-
Addiction/Substance Abuse Treatment
Agents: Opioid Dependence Treatments:
3; (4) Anti-Addiction/Substance Abuse
Treatment Agents: Opioid Reversal
Agents: 1. (Summary at P.5).
2. Preauthorization Required for Inpatient
and Outpatient Substance Use Disorder
Care. "Preauthorization for Mental
Health Services and Substance Abuse
care - Companion Benefit Alternatives,
Inc. (CBA) must preapprove any
inpatient or outpatient treatment for
Mental Health Services and Substance
Abuse care. When Approval isn't
236. See BLUECROSS BLUESHIELD OF S.C., supra note 166; CTRS. FOR MEDICARE &
MEDICAID SERVS., SOUTH CAROLINA 2017 EHB BENCHMARK PLAN,
https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/2017-BMP-
SummarySC-4816.zip (last visited Mar. 14, 2019).
41. SC
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obtained for inpatient Mental Health
Services and Substance Abuse care,
we'll deny covered charges for room and
board. If a Preferred Blue Hospital
doesn't get Approval for you, it can't
bill you for room and board charges.
When Approval isn't obtained for
outpatient Mental Health Services and
Substance Abuse care, we'll reduce
Benefits as shown in your Schedule of
Benefits. If a Preferred Blue Provider
doesn't get Approval for you, it can't
bill you for the reduction. An All Other
Provider, however, can bill you for the
penalty." (P.12).
3. Exclusions. The plan does not cover:
"Sanitarium care or rest cures; long-
term, residential care for the treatment of
Mental Health Services or Substance
Abuse care; and custodial care or
domiciliary care (care meant simply to
help those who can't care for
themselves, such as, but not limited to,
help in walking and getting in and out of
bed, assistance in bathing, dressing,
feeding, using the toilet, preparation of
special diet and supervision of
medications which can usually be self-
administered and which does not require
continuous attention of trained Medical
Personnel)." (P.3 1).
4. Financial Limitation on Substance Use
Disorder Care. "Coinsurance on Mental
Health Services, Substance Abuse care
and Spinal Subluxation Services do not
apply toward your Out-of-pocket
Maximums. These services will be paid
as shown in your Schedule of Benefits
regardless of Out-of-pocket
Maximums." (P.19). "Except for claims
for Mental Health Services, Substance







Abuse care and Spinal Subluxation
Services (if shown in your Schedule of
Benefits), there is a limit to the amount
of Coinsurance you must pay each
Benefit Period if shown in your
Schedule of Benefits for Preferred Blue
Providers and All Other Providers. This
is called your Out-of-pocket Maximum.
It protects you from having to spend
large sums of your own money on health
care. Once you reach the Out-of-pocket
Maximum if shown in your Schedule of
Benefits, claims for covered services
(except for Mental Health Services,
Substance Abuse care and Spinal
Subluxation Services (if shown in your
Schedule of Benefits)) are paid at the
amount shown in the Out-of-pocket
Expenses section of your Schedule of
Benefits for the rest of the Benefit
Period." (P.7).
1. Relevant Prescription Drug Category
and Class Counts. The plan contains the
following relevant prescription drug
category and class counts: (1)
Analgesics: Opioid Analgesics, Long-
acting: 11; (2) Analgesics: Opioid
Analgesics, Short-acting: 14; (3) Anti-
Addiction/Substance Abuse Treatment
Agents: Opioid Dependence Treatments:
1; (4) Anti-Addiction/Substance Abuse
Treatment Agents: Opioid Reversal
Agents: 1. (Summary at P5).
237. See WELLMARK S.D., supra note 170; CTRS. FOR MEDICARE & MEDICAID SERVS.,
SOUTH DAKOTA 2017 EHB BENCHMARK PLAN,










2. Quantitative Treatment Limitation
Applicable to Inpatient Chemical
Dependency Services. The plan covers
thirty (30) days per benefit year of
inpatient chemical dependency services
(although an exception exists for
alcoholism, in which case there is no
limitation) (P.10).
3. Residential Treatment Facility
Limitation. "For treatment in a
residential treatment facility, benefits are
available only if treatment is provided as
an inpatient at an acute level of care with
24-hour registered nursing care under
the supervision of a medical director."
(Pgs. 15-16).
1. Relevant Prescription Drug Category
and Class Counts. The plan contains the
following relevant prescription drug
category and class counts: (1)
Analgesics: Opioid Analgesics, Long-
acting: 10; (2) Analgesics: Opioid
Analgesics, Short-acting: 12; (3) Anti-
Addiction/Substance Abuse Treatment
Agents: Opioid Dependence Treatments:
2; (4) Anti-Addiction/Substance Abuse
Treatment Agents: Opioid Reversal
Agents: 0. (Summary at P.5).
2. Prior Authorization Required for
Inpatient Substance Use Disorder
Treatments. "IMPORTANT NOTE: All
inpatient treatment (including Acute,
residential, and partial hospitalization
238. See BLUECROSS BLUESHIELD OF TENN., EVIDENCE OF COVERAGE (2013),
https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/2017_Benchmark-
SummaryTN.zip (last visited Mar. 14, 2019); CTRS. FOR MEDICARE & MEDICAID SERVS.,
TENNESSEE 2017 EHB BENCHMARK PLAN, https://www.cms.gov/CCIIO/Resources/Data-
Resources/Downloads/2017_Benchmark-SummaryTN.zip (last visited Mar. 14, 2019).
43. TN






and intensive outpatient treatment)
requires Prior Authorization. If You
receive inpatient treatment, including
treatment for substance abuse, that did
not receive Prior Authorization, and You
sign a Provider's waiver stating that You
will be responsible for the cost of the
treatment, You will not receive Plan
benefits for the treatment. You will be
financially responsible, according to the
terms of the waiver." (P.54).
3. Exclusion for Court-Ordered Treatment.
The plan does not cover: "Court ordered
examinations and treatment, unless
Medically Necessary." (P.55).
1. Relevant Prescription Drug Category
and Class Counts. The plan contains the
following relevant prescription drug
category and class counts: (1)
Analgesics: Opioid Analgesics, Long-
acting: 10; (2) Analgesics: Opioid
Analgesics, Short-acting: 12; (3) Anti-
Addiction/Substance Abuse Treatment
Agents: Opioid Dependence Treatments:
2; (4) Anti-Addiction/Substance Abuse
Treatment Agents: Opioid Reversal
Agents: 0. (Summary at P.5).
2. Preauthorization Required for Certain
Treatments of Chemical Dependency.
"Preauthorization is required [for
[certain] treatment of chemical
dependency." (Pgs. 3, 14, 15, and
Amendment).
239. See BLUE CROSS BLUE SHIELD OF TEX., supra note 167; CTRS. FOR MEDICARE &











3. Facility Limitation for Inpatient
Treatment of Chemical Dependency.
"Inpatient treatment must be provided in
a Chemical Dependency Treatment
Center." (P.3)
4. Quantitative Treatment Limitation for
Treatment of Chemical Dependency.
"Three separate series of treatments for
each covered individual per lifetime."
(P.3). "Coverage for treatment of
Chemical Dependency will be limited to
a maximum of three separate series of
treatments for each covered individual."
(P.30).
5. Residential Level of Treatment
Exclusion. The plan does not cover
"Residential level of treatment for
Chemical Dependency in a Chemical
Dependency Treatment Center." (P.48);
"Residential level of treatment for
Chemical Dependency in a Chemical
Dependency Treatment Center." (P.48).
1. Relevant Prescription Drug Category
and Class Counts. The plan contains the
following relevant prescription drug
category and class counts: (1)
Analgesics: Opioid Analgesics, Long-
acting: 8; (2) Analgesics: Opioid
Analgesics, Short-acting: 14; (3) Anti-
Addiction/Substance Abuse Treatment
Agents: Opioid Dependence Treatments:
2; (4) Anti-Addiction/Substance Abuse
Treatment Agents: Opioid Reversal
Agents: 0. (Summary at P.5).
240. See CTRS. FOR MEDICARE & MEDICAID SERVS., UTAH 2017 EHB BENCHMARK
PLAN, https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/2017-BMP-
45. UT
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2. Preauthorization Required for all
Inpatient Mental Health Admissions.
(P.41).
3. Substance Use Disorder Limitations.
The plan establishes the following
limitations applicable to treatment of
substance use disorders: "(1) Benefits
for group family counseling will be
payable under Mental Health for the
primary patient. Benefits will not be
considered separate for each individual
family Member; (2) When an inpatient
stay spans an old and new plan year,
hospital benefits will be based on the old
plan year provisions. Actual number of
days used, how- ever, will apply to
specific plan years; (3) Inpatient
Provider visits are payable only in con-
junction with authorized inpatient days,
and will apply to benefits in effect under
the plan year on the actual date of
service billed; (4) Only one visit per
Provider of the same specialty per day is
payable." (P.32).
4. Mental Health Exclusions. The plan
establishes the following exclusions
applicable to mental health conditions:
"1. Inpatient treatment for Mental Health
without Pre-authorization, if required by
the Member's plan; 2. Milieu therapy,
marriage counseling, encounter groups,
hypnosis, biofeedback, parental
counseling, stress management or
relaxation therapy, conduct disorders,
oppositional disorders, learning
disabilities, and situational disturbances;
SummaryUT-4816.zip (last visited Mar. 14, 2019); PUB. EMP. HEALTH PROGRAM, supra note
168.
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3. mental or emotional conditions
without manifest psychiatric disorder or
non-specific conditions; 4. Wilderness
programs; 5. Inpatient treatment for
behavior modification, enuresis, or
encopresis; 6. Psychological evaluations
or testing for legal purposes such as
custodial rights, etc., or for insurance or
employment examinations; 7.
Occupational or recreational therapy; 8.
Hospital leave of absence charges; 9.
Sodium amobarbital interviews; 10.
Residential treatment programs; 11.
Tobacco abuse; 12. Routine drug
screening, except when ordered by a
treating physician." (P.32).
1. Relevant Prescription Drug Category
and Class Counts. The plan contains the
following relevant prescription drug
category and class counts: (1)
Analgesics: Opioid Analgesics, Long-
acting: 11; (2) Analgesics: Opioid
Analgesics, Short-acting: 12; (3) Anti-
Addiction/Substance Abuse Treatment
Agents: Opioid Dependence Treatments:
2; (4) Anti-Addiction/Substance Abuse
Treatment Agents: Opioid Reversal
Agents: 1. (Summary at P.4).
2. Prior Approval Required for Inpatient,
Partial-Inpatient, Intensive Outpatient,
and Residential Treatment Substance
Use Disorder Benefits. (P.2).
3. Least Restrictive Setting Requirement.
"We Cover substance abuse treatment
241. See BLUECROSS BLUESHIELD OF VT., supra note 172; CTRS. FOR MEDICARE &
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services only if you get Medically
Necessary Care in the least restrictive
setting." (P.16).
4. Exclusions. "We provide no substance
abuse treatment benefits for: services
ordered by a court of law (unless we
deem them Medically Necessary); non-
traditional, alternative therapies such as
eye movement desensitization,
Rubenfeld Synergy, energy polarity
therapy and somatization therapy, that
are not based on American Psychiatric
and American Psychological Association
acceptable techniques and theories;
treatment without ongoing concurrent
review to ensure that treatment is being
provided in the least restrictive setting
required; services, including long-term
residential programs, adventure-based
activities, wilderness programs and
residential programs, that focus on
education, socialization, delinquency or
Custodial Care (see Definitions), as
noted in General Exclusions; Custodial
Care, including housing that is not
integral to a Medically Necessary level
of care or care solely to comply with a
court order, to obtain shelter, to deter
runaway or truant behavior or to achieve
family respite, unless such care is
Medically Necessary (see Definitions),
as noted in General Exclusions; and
biofeedback, pain management, stress
reduction classes and pastoral
counseling." (Pgs. 16-17).
47. VA Anthem Health Plans 1. Relevant Prescription Drug Category
of Virginia (Anthem and Class Counts. The plan contains the
BCBS): following relevant prescription drug
category and class counts: (1)
Analgesics: Opioid Analgesics, Long-
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acting: 14; (2) Analgesics: Opioid
Analgesics, Short-acting: 16; (3) Anti-
Addiction/Substance Abuse Treatment
Agents: Opioid Dependence Treatments:
3; (4) Anti-Addiction/Substance Abuse
Treatment Agents: Opioid Reversal
Agents: 1 (Summary at P.16).
1. Relevant Prescription Drug Category
and Class Counts. The plan contains the
following relevant prescription drug
category and class counts: (1)
Analgesics: Opioid Analgesics, Long-
acting: 11; (2) Analgesics: Opioid
Analgesics, Short-acting: 12; (3) Anti-
Addiction/Substance Abuse Treatment
Agents: Opioid Dependence Treatments:
2; (4) Anti-Addiction/Substance Abuse
Treatment Agents: Opioid Reversal
Agents: 1 (Summary at P.5).
2. Hypnotherapy Exclusion. The plan
excludes from coverage: "Hypnotherapy
and hypnosis services and associated
expenses, including, but not limited to,
use of such services for the treatment of
painful physical conditions, mental
health and substance use disorders or for
anesthesia purposes." (P.21).
49. WV Highmark Blue Cross 1. Relevant Prescription Drug Category
Blue Shield West and Class Counts. The plan contains the
Virginia: following relevant prescription drug
category and class counts: (1)
242. See ANTHEM BLUECROSS BLUESHIELD, supra note 129; CTRS. FOR MEDICARE &
MEDICAID SERVS., VIRGINIA 2017 EHB BENCHMARK PLAN,
https://downloads.cms.gov/cciio/BMP%/`20SummaryVA.zip (last visited Mar. 14, 2019).
243. See REGENCE BLUESHIELD, supra note 173; CTRS. FOR MEDICARE & MEDICAID
SERVS., WASHINGTON 2017 EHB BENCHMARK PLAN,
https://www.assets.regence.com/policy/2017/WA/Silver3000PreferredWashington-dv.pdf (last
visited Mar 14, 2019).
48. WA
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Choice Plus 2 45
Analgesics: Opioid Analgesics, Long-
acting: 11 (2) Analgesics: Opioid
Analgesics, Short-acting: 12; (3) Anti-
Addiction/Substance Abuse Treatment
Agents: Opioid Dependence Treatments:
2; (4) Anti-Addiction/Substance Abuse
Treatment Agents: Opioid Reversal
Agents: 1. (Summary at P.5).
2. Treatability Required. "We do not pay
benefits for Mental Illness that cannot be
treated. We will, pay benefits to
determine if the disorder or illness can
be treated. Your Physician must certify
that there is a reasonable likelihood that
your treatment will be of substantial
benefit and substantial improvement is
likely." (P.32).
1. Relevant Prescription Drug Category
and Class Counts. The plan contains the
following relevant prescription drug
category and class counts: (1)
Analgesics: Opioid Analgesics, Long-
acting: 12; (2) Analgesics: Opioid
Analgesics, Short-acting: 12; (3) Anti-
Addiction/Substance Abuse Treatment
Agents: Opioid Dependence Treatments:
2; (4) Anti-Addiction/Substance Abuse
Treatment Agents: Opioid Reversal
Agents: 0. (Summary at P.5).
2. Prior Authorization Requirement. "For
Non-Network Benefits for a scheduled
244. See CTRS. FOR MEDICARE & MEDICAID SERVS., 2017 EHB BENCHMARK PLAN,
https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/WV-BMP.zip (last visited
Mar. 14, 2019); HIGHMARK BLUE CROSS BLUE SHIELD W. VA., WV GROUP GOLD SHARED
COST PPO $1000: HEALTH CARE CERTIFICATE, https://www.cms.gov/CCIIO/Resources/Data-
Resources/Downloads/WV-BMP.zip (last visited Mar. 14, 2019).
245. See CTRS. FOR MEDICARE & MEDICAID SERVS., WISCONSIN 2017 EHB BENCHMARK
PLAN, https://www.cms.gov/CCIIO/Resources/Data-Resources/Downloads/2017-BMP-
SummaryWI-4816.zip (last visited Mar. 14,2019); UNITEDHEALTHCARE INS., supra note 181.
50. WI
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admission for Substance Use Disorder
Services (including an admission for
Partial Hospitalization/Day Treatment
and services at a Residential Treatment
Facility) you must obtain authorization
prior to the admission or as soon as is
reasonably possible for non-scheduled
admissions (including Emergency
admissions). In addition, for Non-
Network Benefits you must obtain prior
authorization before the following
services are received. Services requiring
prior authorization: Intensive Outpatient
Treatment programs; psychologic al
testing; extended outpatient treatment
visits beyond 45 - 50 minutes in
duration, with or without medication
management. If you fail to obtain prior
authorization as required, Benefits will
be reduced to 50% of Eligible
Expenses." (P.21).
3. Exclusions. The plan excludes coverage
for: Services performed in connection
with conditions not classified in the
current edition of the Diagnostic and
Statistical Manual of the American
Psychiatric Association; Methadone
treatment as maintenance, L.A.A.M. (1-
Alpha-Acetyl-Methadol), Cyclazocine,
or their equivalents;
Educational/behavioral services that are
focused on primarily building skills and
capabilities in communication, social
interaction and learning; Services or
supplies for the diagnosis or treatment of
alcoholism or substance use disorders
that, in the reasonable judgment of the
Mental Health/Substance Use Disorder
Designee, are any of the following: Not
consistent with generally accepted
standards of medical practice for the
846 [VOL. 70: 763
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treatment of such conditions; Not
consistent with services backed by
credible research soundly demonstrating
that the services or supplies will have a
measurable and beneficial health
outcome, and therefore considered
experimental; Not consistent with the
Mental Health/Substance Use Disorder
Designee's level of care guidelines or
best practices as modified from time to
time; and Not clinically appropriate for
the patient's substance use disorder or
condition based on generally accepted
standards of medical practice and
benchmarks. (P.31).
4. Student Limitation. "Coverage will be
provided for the Mental Health clinical
assessments of Dependent Full-time
Students attending school in the State of
Wisconsin but outside of the Service
Area. The clinical assessment must be
conducted by a provider designated by
the Mental Health/Substance Use
Designee and who is located in the State
of Wisconsin and in reasonably close
proximity to the Full-time Student's
school. If outpatient Mental
Health/Substance Use Disorder Services
are recommended, coverage will be
provided for a maximum of 5 visits at an
outpatient treatment facility or other
provider designated by the Mental
Health/Substance Use Disorder
Designee, that is located in the State of
Wisconsin and in reasonably close
proximity to the Full-time Student's
school. Coverage for the outpatient
services will not be provided, if the
recommended treatment would prohibit
the Dependent from attending school on
2019] 847
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a regular basis or if the Dependent is no
longer a Full-time Student." (P.14).
51. WY Blue Cross Blue 1. Relevant Prescription Drug Catego
Shield of Wyoming: and Class Counts. The plan contains the
BlueSelect PPO Silver following relevant prescription drug
for Employer category and class counts: Analgesics:
Groups2 46  Opioid Analgesics, Long-acting: 10; (2)
Analgesics: Opioid Analgesics, Short-
acting: 12; (3) Anti-Addiction/Substance
Abuse Treatment Agents: Opioid
Dependence Treatments: 2; (4) Anti-
Addiction/Substance Abuse Treatment
Agents: Opioid Reversal Agents: 1.
(Summary at P.5).
246. See BLUECROSS BLUESHIELD OF WYO., supra note 144; CTRS. FOR MEDICARE &
MEDICAID SERVS., WYOMING 2017 EHB BENCHMARK PLAN,
https://downloads.cms.gov/cciio/20170%`20Benchmark%/`20SummaryWY revised.zip (last
visited Mar. 14, 2019).
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